




35TH ANNUAL MEETING OF THE ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER
 22-25 April 2026
 Istanbul Lütfi Kırdar International Convention and Exhibition Centre • İstanbul / Türkiye
www.apasi2026istanbul.org



Abstract No	Session Name	Session Date	Session Time	Presenter Name	Presentation Title
1327	APASL - IASL JOINT MEETING	24 April 2026, Friday	13:40 - 15:10	Zhe Dai	VDAC1-ACSL3-mediated aberrant lipid droplet-mitochondria crosstalk to promote HCC in CHB and MASLD coexistence
1726	APASL - IASL JOINT MEETING	24 April 2026, Friday	13:40 - 15:10	Xinrong Zhang	Glucagon-like peptide-1 receptor agonists and reduced liver and non-liver complications in patients with type 2 diabetes and viral hepatitis
2785	APASL - IASL JOINT MEETING	24 April 2026, Friday	13:40 - 15:10	Huan Cheng Cheng	Metabolic Dysfunction Increases the Risk of Liver-related Events in Virologically Suppressed HBV Related Compensated Cirrhosis: Refining Prognostication with the Baveno VI-SSM Model
1067	ORAL PRESENTATION 01	23 April 2026, Thursday	07:30 - 09:00	SREEJITH OZHUKIL THEVARKALATHIL	Clinical Profile and Short-Term Outcomes of Patients with Acute-on-Chronic Liver Failure: A Prospective Observational Study from a Tertiary Center in Southern India
1079	ORAL PRESENTATION 01	23 April 2026, Thursday	07:30 - 09:00	Ngan Le Thanh Quynh	Prognostic utility of the MELD score and AE model in predicting acute-on-chronic liver failure among patients with severe acute exacerbation of chronic hepatitis B.
1189	ORAL PRESENTATION 01	23 April 2026, Thursday	07:30 - 09:00	YAO ZHANG	VISTA deficiency exacerbates the development of acute-on-chronic liver failure by promoting Tc1 Differentiation
1201	ORAL PRESENTATION 01	23 April 2026, Thursday	07:30 - 09:00	Bandar Aljudaibi	Outcomes of Living Donor Liver Transplantation in Patients with or without Acute-on-Chronic Liver Failure: A Single Centre Experience
1239	ORAL PRESENTATION 01	23 April 2026, Thursday	07:30 - 09:00	xueshi zhou	Study on the Value of Antithrombin III Activity Combined with COSSH-ACLF Score in Predicting the Prognosis of HBV-ACLF Patients in the Intensive Care Unit
1252	ORAL PRESENTATION 01	23 April 2026, Thursday	07:30 - 09:00	Dr Kapil Kumar Kumar	Clinical Trajectories of Acute Decompensation in Cirrhosis: The First Prospective PREDICT-Based Study from India
1338	ORAL PRESENTATION 01	23 April 2026, Thursday	07:30 - 09:00	Jingjing Chen	Validation of the 2025 Global Expert Panel Consensus Definition of ACLF in Real-World Hospitalized Patients With Cirrhosis
1384	ORAL PRESENTATION 01	23 April 2026, Thursday	07:30 - 09:00	Tatsuo Kanda	Hepatitis A and E Guidelines created by the Japan Agency for Medical Research and Development (AMED) HAV and HEV Study Group
1385	ORAL PRESENTATION 01	23 April 2026, Thursday	07:30 - 09:00	Pengfei Yu	Direct chemical reprogramming of urine-derived stem cells from acute-on-chronic liver failure patients into hepatocyte-like organoids to attenuate liver injury
1156	ORAL PRESENTATION 02	23 April 2026, Thursday	07:30 - 09:00	Qiao Wei	Contrast-enhanced Ultrasound Features of Combined hepatocellular carcinoma and cholangiocarcinoma (HCC-CC): A Case Series Report
1179	ORAL PRESENTATION 02	23 April 2026, Thursday	07:30 - 09:00	MANISH KUMAR	Association of Urinary Spot Sodium-Potassium Ratio with Acute Kidney Injury in Decompensated Cirrhosis
1335	ORAL PRESENTATION 02	23 April 2026, Thursday	07:30 - 09:00	Adela Turcanu	A 7-item discharge risk index predicts 12-month decompensation in HDV cirrhosis: derivation and external validation
2742	ORAL PRESENTATION 02	23 April 2026, Thursday	07:30 - 09:00	Jasmohan Bajaj	PREDICTION OF NOSOCOMIAL INFECTION DEVELOPMENT REMAINS SUBOPTIMAL DESPITE USING MACHINE LEARNING TECHNIQUES IN A PROSPECTIVE GLOBAL COHORT OF HOSPITALIZED CIRRHOSIS PATIENTS
2789	ORAL PRESENTATION 02	23 April 2026, Thursday	07:30 - 09:00	SHREYAS SARVESH	Comparison of the Safety and Efficacy of Tailored versus Fixed-Dose Albumin in Cirrhosis with Sepsis-Associated Acute Kidney Injury: A Randomised Controlled Trial
2841	ORAL PRESENTATION 02	23 April 2026, Thursday	07:30 - 09:00	Fan Li	PLPP2 drives liver repair and regeneration via remodeling phosphatidylethanolamine metabolism after acute liver injury
2879	ORAL PRESENTATION 02	23 April 2026, Thursday	07:30 - 09:00	Jaifrin Daniel	AAFC score predicts survival in patients with Acute on Chronic Liver Failure due to Severe Alcoholic Hepatitis undergoing Plasma Exchange
2894	ORAL PRESENTATION 02	23 April 2026, Thursday	07:30 - 09:00	Sudhir Verma	Splenic probe (100 kPa) is superior to liver probe (75 kPa) in assessment of liver stiffness and predicting outcomes in Acute on chronic liver failure patients
1126	ORAL PRESENTATION 03	23 April 2026, Thursday	07:30 - 09:00	Helin ÖZALKAN	Development of a Dual-Module Artificial Intelligence System for Non-Invasive Staging of Liver Fibrosis Using Blood Tests and Ultrasound Images
1127	ORAL PRESENTATION 03	23 April 2026, Thursday	07:30 - 09:00	Beyzanur BAYIR	Development of a Multi-Modal Artificial Intelligence Assistant for Early Diagnosis of Hepatocellular Carcinoma Using Imaging and Laboratory Data
1157	ORAL PRESENTATION 03	23 April 2026, Thursday	07:30 - 09:00	Jialin Chen	Predictive Model for Targeted Combination Immunotherapy Efficacy in Unresectable Hepatocellular Carcinoma Patients Based on Multimodal MRI Radiomics (MC-hcAI 007): A Multicenter Study
1278	ORAL PRESENTATION 03	23 April 2026, Thursday	07:30 - 09:00	Mucong Yu	Small lesion oriented early hepatocellular carcinoma segmentation via a hybrid-attention deformable U-Net
1341	ORAL PRESENTATION 03	23 April 2026, Thursday	07:30 - 09:00	Engin Altinkaya	Screening of new active molecules derived from ursodiol in the treatment of primary biliary cholangitis and ursodeoxycholic acid
1476	ORAL PRESENTATION 03	23 April 2026, Thursday	07:30 - 09:00	Chuan Pang	Prediction of microvascular invasion in HCC using spatiotemporal radiomics of contrast-enhanced ultrasound: a deep learning model with tumor microenvironment correlation
1785	ORAL PRESENTATION 03	23 April 2026, Thursday	07:30 - 09:00	Cong Wang	Automatic Detection of Hepatocellular Carcinoma on MRI Using a Lesion-Aware Fine-Tuning Framework
2268	ORAL PRESENTATION 03	23 April 2026, Thursday	07:30 - 09:00	Haoran Sun	Interpretable AI That "Reads the Liver From the Face": A 3D-Face Digital Biomarker for Ultrasound-Confirmed NAFLD
2300	ORAL PRESENTATION 03	23 April 2026, Thursday	07:30 - 09:00	Mehmet Yıldız	Old Drugs, New Targets: Repurposing Proton Pump Inhibitors for Autoimmune Liver Diseases: Molecular Docking Insights into the TLR4/MD-2, NLRP3, and C5aR1 Axes
1238	ORAL PRESENTATION 04	23 April 2026, Thursday	07:30 - 09:00	Hasan Eruzun	Awareness of Primary Biliary Cholangitis Among Turkish Physicians: An Online Survey
1263	ORAL PRESENTATION 04	23 April 2026, Thursday	07:30 - 09:00	Yusuf Bünyamin Ketenci	The Paradox of Size: A Non-Linear Relationship Between Liver Size and Fibrosis Stage in Acute Autoimmune Hepatitis
1447	ORAL PRESENTATION 04	23 April 2026, Thursday	07:30 - 09:00	Ahad Eshraghian	N acetyl cysteine plus corticosteroid versus corticosteroid alone for treatment of acute severe autoimmune hepatitis: a randomized clinical trial
1768	ORAL PRESENTATION 04	23 April 2026, Thursday	07:30 - 09:00	Chao Cai	ALT Trajectories Differentiated by Early Treatment Response Determine Long-Term Outcomes in Autoimmune Hepatitis
1775	ORAL PRESENTATION 04	23 April 2026, Thursday	07:30 - 09:00	Wenxuan Shang	Longitudinal Analysis Reveals Comparable ALT Trajectories and Achievement of Biochemical Remission Regardless of Baseline Fibrosis in Autoimmune Hepatitis
1883	ORAL PRESENTATION 04	23 April 2026, Thursday	07:30 - 09:00	Christine Velasquez	Early-Onset PSC With Recurrent Cholangitis Requiring Early Transplant Evaluation: A Five-Year Case Trajectory and Prelude to the Transplant Course
2148	ORAL PRESENTATION 04	23 April 2026, Thursday	07:30 - 09:00	YunLong Yao	B-Cell Depletion Therapy Shows Efficacy in Steroid-Refractory Autoimmune Hepatitis
2335	ORAL PRESENTATION 04	23 April 2026, Thursday	07:30 - 09:00	Manal Cherkaoui Malki	Assessment of Autoimmune Hepatitis Severity According to Autoantibody Profile
2433	ORAL PRESENTATION 04	23 April 2026, Thursday	07:30 - 09:00	Mubin Ozercan	Diagnostic performance of non-invasive fibrosis scores in treatment-naïve patients with autoimmune hepatitis
1197	ORAL PRESENTATION 05	23 April 2026, Thursday	07:30 - 09:00	Ling Xu	Enhancement of Liver Regeneration in Mice through DDX3X-CD36 Pathway-Mediated Promotion of Hepatic Lipid Accumulation
1266	ORAL PRESENTATION 05	23 April 2026, Thursday	07:30 - 09:00	Liwei Zeng	The quality and reliability of short videos about liver cirrhosis on Bilibili and TikTok: Cross-sectional study
1311	ORAL PRESENTATION 05	23 April 2026, Thursday	07:30 - 09:00	Danish Ahmed	Liver-Centric Therapeutic Profiling of 2β-Hydroxybetulinic Acid-3β-Caprylate (HBAC): A Phyto-Derived Modulator of Hepatic Redox Balance, Gluconeogenesis and Lipotoxic Stress in Experimental Diabetes
1336	ORAL PRESENTATION 05	23 April 2026, Thursday	07:30 - 09:00	Tushar Prabhakar	Can poor sleep signal fatty liver disease? Evidence from a rural population in North India
1387	ORAL PRESENTATION 05	23 April 2026, Thursday	07:30 - 09:00	Chaiyaboot Ariyachet	The transcription factor PRDM5 is a novel pro-fibrotic factor in liver fibrosis
1559	ORAL PRESENTATION 05	23 April 2026, Thursday	07:30 - 09:00	Xue Zhang	SIRPA as a Novel Regulator of T Cell Apoptosis in Hepatocellular Carcinoma: Implications for Immunotherapy
1679	ORAL PRESENTATION 05	23 April 2026, Thursday	07:30 - 09:00	Naseer Kawish	PASSIVE TOBACCO SMOKE INDUCED CHANGES IN THE EXPRESSION OF IRON METABOLISM GENES IN MOUSE PUPS
1783	ORAL PRESENTATION 05	23 April 2026, Thursday	07:30 - 09:00	Soner KARABULUT	LLGL1 Loss Attenuates Hippo Signaling and Sustains Pro-oncogenic YAP Activity in Hepatocellular Carcinoma Cells
1836	ORAL PRESENTATION 05	23 April 2026, Thursday	07:30 - 09:00	Jingran Jiao	Trends in hepatitis B-related diseases in Asia, 1990-2023: an analysis of the Global Burden of Disease 2023 update
1708	ORAL PRESENTATION 06	23 April 2026, Thursday	07:30 - 09:00	Xiaoxiao Wang	Males are emerging as the primary high-risk population for gallbladder and biliary tract cancers
1909	ORAL PRESENTATION 06	23 April 2026, Thursday	07:30 - 09:00	Cleo Christille Lynn Lom-oc	A Diagnostic conundrum in a Case of Obstructive Jaundice in Biliary Hamartoma
2145	ORAL PRESENTATION 06	23 April 2026, Thursday	07:30 - 09:00	Ahmet Uyanikoglu	Gestational cholestasis: single center experience
2395	ORAL PRESENTATION 06	23 April 2026, Thursday	07:30 - 09:00	Zhigang Ren	Multicohort fecal metagenomes analysis contributes to non-invasive diagnosis for cholangiocarcinoma
2439	ORAL PRESENTATION 06	23 April 2026, Thursday	07:30 - 09:00	Bilal ALTUNISIK	A silent threat: A case of infiltrative cholangiocellular carcinoma developing without detectable mass
2518	ORAL PRESENTATION 06	23 April 2026, Thursday	07:30 - 09:00	shasha li	Antinuclear Antibodies Positivity Indicates a High-inflammatory Phenotype in Primary Biliary Cholangitis: A Multicenter Retrospective Analysis
2596	ORAL PRESENTATION 06	23 April 2026, Thursday	07:30 - 09:00	Phool Chand	Baseline Determinants of Inadequate Ursodeoxycholic Acid Response in Primary Biliary Cholangitis: A POISE-Based Real-World Cohort Study
1346	ORAL PRESENTATION 07	23 April 2026, Thursday	07:30 - 09:00	Gabriel Daniel Alcantara	A Ductless Dilemma: Pembrolizumab Induced versus Paraneoplastic Vanishing Bile Duct Syndrome
1362	ORAL PRESENTATION 07	23 April 2026, Thursday	07:30 - 09:00	Xiaoyu Huang	Cell-Microcapsule-Loaded Potent Nanoenzymes Alleviate Drug-Induced Liver Injury via Dual Strategies
1656	ORAL PRESENTATION 07	23 April 2026, Thursday	07:30 - 09:00	Suwen Jiang	Analysis on the differences of clinicopathological characteristics in drug-induced liver injury patients with positive or negative autoantibodies and different clinical types
1722	ORAL PRESENTATION 07	23 April 2026, Thursday	07:30 - 09:00	Jasmin Gondayao	Paraneoplastic Hyperbilirubinemia in Hodgkin's Lymphoma: An Uncommon Presentation with Significant Diagnostic and Therapeutic Challenges
2125	ORAL PRESENTATION 07	23 April 2026, Thursday	07:30 - 09:00	Yong Liu	Efficacy and Safety of Magnesium Isoglycyrrhizinate in Checkpoint Inhibitor-Induced Liver Injury in Patients with Advanced Solid Tumors: An Exploratory Study
2604	ORAL PRESENTATION 07	23 April 2026, Thursday	07:30 - 09:00	Hua Liu	Research on artificial liver support system for non-hepatocellular carcinoma patients with severe immune checkpoints related liver injury
2606	ORAL PRESENTATION 07	23 April 2026, Thursday	07:30 - 09:00	Rongtao Lai	A Simple Five-Variable Model Integrating GWAS Variants Predicts Chronic Outcomes in Drug Induced Liver Injury




35TH ANNUAL MEETING OF THE ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER
22-25 April 2026
Istanbul Lütfi Kırdar International Convention and Exhibition Centre • İstanbul / Türkiye
www.apasl2026istanbul.org



Abstract No	Session Name	Session Date	Session Time	Presenter Name	Presentation Title
2814	ORAL PRESENTATION 07	23 April 2026, Thursday	07:30 - 09:00	Duygu Birinci	Etiological distribution, clinical phenotypes and six-month outcomes of drug-induced liver injury: a single-center cohort study
1133	ORAL PRESENTATION 08	23 April 2026, Thursday	07:30 - 09:00	Xueyan Lin	A Novel HFE Mutation C.1006+1G>A Disrupts Iron Homeostasis and Drives Hereditary Hemochromatosis Pathogenesis
1456	ORAL PRESENTATION 08	23 April 2026, Thursday	07:30 - 09:00	anum LIAQUAT ALI	Determination of Ankyrin Repeats Domain (ANK) of RNASE L Gene in Hepatitis C Patients and its effects on Viral Load
1494	ORAL PRESENTATION 08	23 April 2026, Thursday	07:30 - 09:00	Zhenhua Zhang	Distinct Clinical Profile of Wilson Disease-Related Cirrhosis: Insights from a Propensity Score-Matched Multicenter Study
1672	ORAL PRESENTATION 08	23 April 2026, Thursday	07:30 - 09:00	Veronica Cumpata	Hepatic steatosis in Wilson disease: phenotype or metabolic comorbidity?
1897	ORAL PRESENTATION 08	23 April 2026, Thursday	07:30 - 09:00	Sujun Zheng	Genotype-Phenotype Correlation of ATP7B Mutations in Wilson Disease
1916	ORAL PRESENTATION 08	23 April 2026, Thursday	07:30 - 09:00	Jiaqi Li	Restoration of ATP7B Trafficking and Biliary Function in Wilson Disease Hepatocytes through CRISPR/Cas9-Mediated Gene Correction
1941	ORAL PRESENTATION 08	23 April 2026, Thursday	07:30 - 09:00	Anmol Anmol	Predictors and Immune Signatures of Baveno-VII–Aligned Recompensation in Pediatric Wilson Disease with Decompensated Cirrhosis
2134	ORAL PRESENTATION 08	23 April 2026, Thursday	07:30 - 09:00	Yue Han	Iron Metabolism Defects in Wilson Disease Suspects - A Real-World Two-Phase Molecular Epidemiology Study
2314	ORAL PRESENTATION 08	23 April 2026, Thursday	07:30 - 09:00	Sujun Zheng	Gilbert syndrome increases the risk of gallstone disease: a cross-sectional study based on health examination data from 338,372 adults
1101	ORAL PRESENTATION 09	23 April 2026, Thursday	07:30 - 09:00	seda zor	Association of Serum ALT Levels with Histological Activity and Fibrosis in Chronic Hepatitis B
1130	ORAL PRESENTATION 09	23 April 2026, Thursday	07:30 - 09:00	Mehmet Raşit Ayte	Effects of COVID-19 Vaccines on HBV Replication in Patients with Chronic Hepatitis B: A Comparative Analysis of mRNA and Inactivated Vaccines
1132	ORAL PRESENTATION 09	23 April 2026, Thursday	07:30 - 09:00	Zeynep Tekin Taş	POTENTIAL HERB-DRUG INTERACTIONS IN CHRONIC HEPATITIS B TREATMENT: A CASE SERIES
1153	ORAL PRESENTATION 09	23 April 2026, Thursday	07:30 - 09:00	David Hilmers	A Pilot Program of Community Volunteers to Improve Adherence to Hepatitis B Medications in Kiribati
1163	ORAL PRESENTATION 09	23 April 2026, Thursday	07:30 - 09:00	Zihao Fan	One‐Pot Assay Based on CRISPR/Cas13a Technology for HEV RNA Point‐of‐Care Testing
1168	ORAL PRESENTATION 09	23 April 2026, Thursday	07:30 - 09:00	Feng Ren	Peginterferon alpha-2b and nucleos(t)ide analogs combination therapy for chronic hepatitis B patients with high HBSAg level at the end of treatment (52 weeks) from ongoing CREATED Excellent Study
1173	ORAL PRESENTATION 09	23 April 2026, Thursday	07:30 - 09:00	Xiaoxin Wu	Unfolding Clinical Research Landscape on Bacterial Infections in Cirrhosis: Trends, Hotspots, and Analytical Insights
1204	ORAL PRESENTATION 09	23 April 2026, Thursday	07:30 - 09:00	Taiyu He	Sequential therapy with anti-PD-1 antibody and pegylated interferon-alpha promoted HBSAg reduction and enhanced T cell response in patients with chronic hepatitis B
1229	ORAL PRESENTATION 09	23 April 2026, Thursday	07:30 - 09:00	Jia Liu	PD-1 is required for the early expansion of HBV-specific CD8+ T cells and does not suppress their effector function during the acute phase of HBV infection
2580	ORAL PRESENTATION 10	23 April 2026, Thursday	09:00 - 10:30	Luyu Wang	PYGL: A novel non-invasive biomarker for diagnostic and prognostic of HEV-ALF patients
2590	ORAL PRESENTATION 10	23 April 2026, Thursday	09:00 - 10:30	Fadhyl Zuhry Lubis	The Predictive Value of Platelet-Derived Growth Factor for Evaluating Antiviral Therapy Response and Liver Stiffness Trajectory in Chronic Hepatitis B
2600	ORAL PRESENTATION 10	23 April 2026, Thursday	09:00 - 10:30	Muhsin Murat Muhip HARPULUOĞLU	Hepatitis B virus recurrence in liver transplant recipients receiving subcutaneous hepatitis B immunoglobulin
2601	ORAL PRESENTATION 10	23 April 2026, Thursday	09:00 - 10:30	İLYAS ETHEM ŞENÖCAK	Diagnostic Accuracy and Long-Term Prognostic Value of FIB-4 Index and De Ritis Ratio in Chronic Hepatitis C Patients: A Comparative Kaplan-Meier Analysis with MELD 3.0
2608	ORAL PRESENTATION 10	23 April 2026, Thursday	09:00 - 10:30	Yuchen Peng	Optimizing Pegylated Interferon Consolidation Therapy and Predicting Recurrence After Functional Cure in Chronic Hepatitis B: A Study Based on Updated Definitions
2630	ORAL PRESENTATION 10	23 April 2026, Thursday	09:00 - 10:30	Liu Yang	Single-cell transcriptomes reveal the immune characteristics of patients with chronic hepatitis B at different stages of disease progression
2663	ORAL PRESENTATION 10	23 April 2026, Thursday	09:00 - 10:30	Müge Toygar Deniz	High Prevalence of MASLD and MASH in Chronic Hepatitis B Patients: A Cross-Sectional Study
2711	ORAL PRESENTATION 10	23 April 2026, Thursday	09:00 - 10:30	Xiucheng Pan	Related Factors for Low-Level Viremia and the Comparative Efficacy of Management Strategies in Treatment-Naive Chronic Hepatitis B Patients Receiving Entecavir or Tenofovir Amibufenamide: A Real-World Study
2729	ORAL PRESENTATION 10	23 April 2026, Thursday	09:00 - 10:30	Yuhao Wang	Lactate triggers HBV-Specific CD8+ T cell exhaustion through mitophagy suppression mediated mitochondrial dysfunction
1232	ORAL PRESENTATION 11	23 April 2026, Thursday	17:10 - 18:30	EMİN EDİZ TÛTÛNCÛ	Preoperative Viral Hepatitis Screening: Evaluation of the Consultation Chain
1272	ORAL PRESENTATION 11	23 April 2026, Thursday	17:10 - 18:30	Qinzhì Deng	Comparing two intervention strategies to improve hepatitis B virus deoxyribonucleic acid testing rate among hepatitis B surface antigen-positive hospitalized patients
1277	ORAL PRESENTATION 11	23 April 2026, Thursday	17:10 - 18:30	Orçun Barkay	Evaluation of Treatment Response in Chronic Hepatitis C Patients Receiving Sofosbuvir/Velpatasvir/Voxilaprevir: A Multicenter Real-World Experience from Türkiye
1331	ORAL PRESENTATION 11	23 April 2026, Thursday	17:10 - 18:30	Emrullah ATAŞ	Evaluation of Hepatitis B Serology, Vaccination Rate, and Reactivation in Hepatitis C Patients Treated with Direct-Acting Antivirals
1344	ORAL PRESENTATION 11	23 April 2026, Thursday	17:10 - 18:30	SL Currie	A single VRON-0200 prime dose induced sustained and/or continued HBSAg declines up to one-year post dosing, and rapid HBSAg declines with addition of antiviral agents, in chronically HBV-infected patients
1353	ORAL PRESENTATION 11	23 April 2026, Thursday	17:10 - 18:30	Shan Ren	30% of Inactive HBSAg Carriers Achieved Clinical Cure at 48 Weeks with Pegylated Interferon Alpha-2b Therapy: A Multicenter Real-World Study (STARHB Project in China)- 3 years Data Update
1375	ORAL PRESENTATION 11	23 April 2026, Thursday	17:10 - 18:30	Yujuan Guan	Multidimensional analysis of diagnosis and treatment status of chronic hepatitis B
1399	ORAL PRESENTATION 11	23 April 2026, Thursday	17:10 - 18:30	Lin Tuo	Trajectory-Based Multidimensional Risk Scoring in a Single-Center Retrospective Cohort: Exploratory Development for Predicting Poor HBSAg Seroclearance Response in Chronic Hepatitis B Functional Cure
1410	ORAL PRESENTATION 11	23 April 2026, Thursday	17:10 - 18:30	Zhao Qian	Characterization of Serum Cytokine Profile and Its Early-Warning Value in Elderly Patients with Hepatitis E
1832	ORAL PRESENTATION 12	23 April 2026, Thursday	18:30 - 20:00	ADRIAN BUGAYONG	An Unexpected Turmoil: Hepatitis B Reactivation with Atypical Serology Following Neoadjuvant Capecitabine-Oxaliplatin in an Unsuspected Patient with Gastric Adenocarcinoma: A Multidisciplinary Management Complexity
1861	ORAL PRESENTATION 12	23 April 2026, Thursday	18:30 - 20:00	HATUN ÖZTÛRK ÇERİK	Test, Treat!: A Small Step For The World, A Big Step For Us; Hepatitis C Microelimination Efforts in a Small City in Türkiye
1886	ORAL PRESENTATION 12	23 April 2026, Thursday	18:30 - 20:00	Mengji Lu	The role of Alix and VPS4A in autophagy and endosomal pathways and their relation to HBV replication
1912	ORAL PRESENTATION 12	23 April 2026, Thursday	18:30 - 20:00	Xiao-hao Wang	Association Between Fatty Liver and Risk of Liver Failure in Patients with Acute Hepatitis B: A Retrospective Cohort Study
1920	ORAL PRESENTATION 12	23 April 2026, Thursday	18:30 - 20:00	ESMA ASLIHAN AYDEMİR	A New Noninvasive Marker Predicting Liver Fibrosis in Patients with Chronic Hepatitis B
1926	ORAL PRESENTATION 12	23 April 2026, Thursday	18:30 - 20:00	Sümeyra İstek	Hepatitis and HIV Seroprevalence in Individuals with Substance Use Disorders: A 25-Year Retrospective Analysis
1967	ORAL PRESENTATION 12	23 April 2026, Thursday	18:30 - 20:00	Lu Zhang	Hepatitis C Virus Micro‑elimination in the Hospital Setting: What Results Have We Achieved?
1984	ORAL PRESENTATION 12	23 April 2026, Thursday	18:30 - 20:00	Gule Cinar	Comparative Efficacy of Entecavir and Tenofovir Disoproxil Fumarate in Preventing HBV Reactivation in Patients Receiving Biologic Disease-Modifying Antirheumatic Drugs
2002	ORAL PRESENTATION 12	23 April 2026, Thursday	18:30 - 20:00	Jacky Man Chun Chan	Acute Hepatitis B Infection Following Long‑Acting Injectable Antiretroviral Therapy Drug Switch in HIV
1010	ORAL PRESENTATION 13	23 April 2026, Thursday	18:30 - 20:00	Maria Diana Manalili	A Five-Year Retrospective Analysis of Hepatic Fibrosis and Steatosis Assessed by Transient Elastography in Patients Across the Glycemic Continuum
1042	ORAL PRESENTATION 13	23 April 2026, Thursday	18:30 - 20:00	Xinjie Li	Non-invasive detection of occult yet significant liver pathology in ALT-normal chronic hepatitis B: a multicenter study
1046	ORAL PRESENTATION 13	23 April 2026, Thursday	18:30 - 20:00	Thong Vo Duy	EVALUATING THE PROGNOSTIC VALUE OF THE MELD 3.0 SCORE IN PREDICTING MORTALITY IN CIRRHOSIS PATIENTS WITH ACUTE VARICEAL BLEEDING
1051	ORAL PRESENTATION 13	23 April 2026, Thursday	18:30 - 20:00	Ching Sheng Hsu	Physical performance is associated with severe liver fibrosis in patients with chronic liver disease
1147	ORAL PRESENTATION 13	23 April 2026, Thursday	18:30 - 20:00	Zeyi Zhang	Global, regional, and national burdens of cirrhosis in adolescents and young adults from 1990 to 2021
1190	ORAL PRESENTATION 13	23 April 2026, Thursday	18:30 - 20:00	Qiong Wu	Macrophage Nr1-Foxo1-KLF6 Axis Drives Mitochondrial Dysfunction and Inflammatory Progression in Liver Fibrosis
1283	ORAL PRESENTATION 13	23 April 2026, Thursday	18:30 - 20:00	Chun-Ting Ho	Diagnostic Performance of Non-Invasive Serum Biomarkers for Fibrosis in Hepatocellular Carcinoma Patients With Metabolic Dysfunction–Associated Steatotic Liver Disease
1289	ORAL PRESENTATION 13	23 April 2026, Thursday	18:30 - 20:00	Rui Huang	Computed tomography-based hepatosplenic volumetry can predict all-cause and liver-related mortality in patients with cirrhosis
1312	ORAL PRESENTATION 13	23 April 2026, Thursday	18:30 - 20:00	Yi-Chun Wang	Multiparametric magnetic resonance imaging to risk-stratify patients with chronic liver disease: Descriptive results from the ELEGANCE study
1804	ORAL PRESENTATION 14	23 April 2026, Thursday	18:30 - 20:00	Wen Zhang	LOXL1 G153D Mutation Impairs Liver Fibrosis Regression by Enhancing Extracellular Matrix Stabilization
1805	ORAL PRESENTATION 14	23 April 2026, Thursday	18:30 - 20:00	Chenxue Hou	Clinical Validation and Diagnostic Value Assessment of Plasma GSTM3 as a Novel Biomarker for Liver Fibrosis
1816	ORAL PRESENTATION 14	23 April 2026, Thursday	18:30 - 20:00	Hong Li	The roles of THBS2-SPP1 axis in hepatic stellate cells activation and liver fibrogenesis
1818	ORAL PRESENTATION 14	23 April 2026, Thursday	18:30 - 20:00	Wenyue Wu	Selective Inhibition of Hepatic Stellate Cell-Derived Microfibril-associated glycoprotein 4 Attenuates Liver Fibrosis
1843	ORAL PRESENTATION 14	23 April 2026, Thursday	18:30 - 20:00	Yuanying Zhao	Gut-Liver Axis Mechanisms Underlying Spontaneous Reversal of Liver Fibrosis: A Gut Microbiota-Metabolomics Analysis
1889	ORAL PRESENTATION 14	23 April 2026, Thursday	18:30 - 20:00	Junhao Zha	Liver Fibrosis: Explainable Deep learning Network for Automated Staging by Using Equilibrium Enhanced Phase MR Images
1934	ORAL PRESENTATION 14	23 April 2026, Thursday	18:30 - 20:00	Hakan Demiröz	Comprehensive Evaluation of Demographic, Endoscopic, and Ultrasonographic Characteristics in First Episode Variceal Bleeding




35TH ANNUAL MEETING OF THE ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER
 22-25 April 2026
 Istanbul Lütfi Kırdar International Convention and Exhibition Centre • İstanbul / Türkiye
www.apasl2026istanbul.org



Abstract No	Session Name	Session Date	Session Time	Presenter Name	Presentation Title
2047	ORAL PRESENTATION 14	23 April 2026, Thursday	18:30 - 20:00	Zizhen Ye	Controlled expansion stent-grafts in TIPS: a real-world analysis of in vivo diameter change and early hepatic encephalopathy
2117	ORAL PRESENTATION 14	23 April 2026, Thursday	18:30 - 20:00	Tong Bu	Clinical Characteristics and Short-Term Outcomes of Patients with Cirrhosis and Subclinical Decompensation
1009	ORAL PRESENTATION 15	23 April 2026, Thursday	18:30 - 20:00	Jai Young Cho	Liver Resection versus Trans-arterial Chemoembolization for Huge Hepatocellular carcinoma (>10cm): A nationwide Propensity score adjusted analysis
1034	ORAL PRESENTATION 15	23 April 2026, Thursday	18:30 - 20:00	Yingcheng Wu	Charting immune and cancer metabolism co-evolution during metastasis
1035	ORAL PRESENTATION 15	23 April 2026, Thursday	18:30 - 20:00	Tongguo Miao	Targeting PAK1 on tumour-associated macrophages enhances the efficacy of immunotherapy in hepatocellular carcinoma
1481	ORAL PRESENTATION 15	23 April 2026, Thursday	18:30 - 20:00	Xin Wen	Development and validation of brain age clock from psychometric hepatic encephalopathy score for early detection of hepatic encephalopathy
1940	ORAL PRESENTATION 15	23 April 2026, Thursday	18:30 - 20:00	MOHD. IBRAHIM KHAN	Dual SGLT2-DPP-4 Inhibition Synergistically Restores Hepatopancreatic Integrity in Experimental Diabetes
2041	ORAL PRESENTATION 15	23 April 2026, Thursday	18:30 - 20:00	Ferdinand Anzo	A Rare Presentation of Salmonella enteritidis Bacteremia With Coronary Mycotic Aneurysm and Non-Cirrhotic Portal Hypertension
2364	ORAL PRESENTATION 15	23 April 2026, Thursday	18:30 - 20:00	Oğuzhan Acet	Hepatic Involvement and Drug-Induced Liver Injury in Brucellosis
2378	ORAL PRESENTATION 15	23 April 2026, Thursday	18:30 - 20:00	Tong Chen	Metabolic Dysfunction-Associated Liver Disease and Lung Injury: A Decade of Progress Toward Mechanistic Integration and Translational Insight
2774	ORAL PRESENTATION 15	23 April 2026, Thursday	18:30 - 20:00	Wanyue Cao	Adipose-derived FABP5 drives myeloid bias in hematopoietic stem cells and promotes tumor progression.
1039	ORAL PRESENTATION 16	23 April 2026, Thursday	18:30 - 20:00	Deyuan Zhong Zhong	Preoperative TACE with PD-1 Inhibitors and TKIs in Beyond "Up-to-Seven" Hepatocellular Carcinoma: A Propensity Score Matched Analysis
1065	ORAL PRESENTATION 16	23 April 2026, Thursday	18:30 - 20:00	Xiaoyan Chi	Epigenetic regulation and functional mechanisms of the ZSCAN23 gene in liver cancer
1096	ORAL PRESENTATION 16	23 April 2026, Thursday	18:30 - 20:00	Yuxin Liang	Triplet Therapy with Envafolelimab, Lenvatinib, and TACE Enables Curative Conversion and Pathological Response in Unresectable HCC: A Single-Arm Phase II study
1116	ORAL PRESENTATION 16	23 April 2026, Thursday	18:30 - 20:00	Muhammad Rezki Rasyak	Racial Disparities in Hepatocellular Carcinoma: A TCGA-Based Gene Expression Study of Caucasian and Asian Populations
1118	ORAL PRESENTATION 16	23 April 2026, Thursday	18:30 - 20:00	Rui Zhao	Targeting Premalignant Liver Lesions with Dietary Bioactive Compounds: From Multi-Targeted Mechanisms to Precision Prevention
1140	ORAL PRESENTATION 16	23 April 2026, Thursday	18:30 - 20:00	Liyang Ren	EEF1E1 sustains EGF signaling to drive immune evasion and tumor progression in hepatocellular carcinoma
1141	ORAL PRESENTATION 16	23 April 2026, Thursday	18:30 - 20:00	Xianglong Chen	Sequential met inhibition from crizotinib to capmatinib in a patient with advanced met-amplified intrahepatic cholangiocarcinoma: a case report
1149	ORAL PRESENTATION 16	23 April 2026, Thursday	18:30 - 20:00	Yao Yang	Dead-box helicase1 promote cancer stemness of hepatocellular carcinoma by enhancing FSCN1 mRNA translation
1245	ORAL PRESENTATION 16	23 April 2026, Thursday	18:30 - 20:00	Chien-Wei Su	Combined Application of Serum Alpha-Fetoprotein and PIVKA-II Levels for Prognostic Stratification in Patients With Hepatocellular Carcinoma
2359	ORAL PRESENTATION 17	23 April 2026, Thursday	18:30 - 20:00	Kyoko Oura	Stage-Specific Survival in Hepatocellular Carcinoma: A Multiregional Analysis Across Japan vs Non-Japan Cohorts in the Asia-Pacific Region
2418	ORAL PRESENTATION 17	23 April 2026, Thursday	18:30 - 20:00	Maria Fleurdeliz Goco-Siatan	AFP trajectories in HCC after ablation treatment: a 15 year retrospective study
2454	ORAL PRESENTATION 17	23 April 2026, Thursday	18:30 - 20:00	ONUR DURNA	Anticancer Effects of Bromelain on HUH7 Hepatocellular Carcinoma Cells through Modulation of the EGFR/PI3K Pathway
2460	ORAL PRESENTATION 17	23 April 2026, Thursday	18:30 - 20:00	Akshyata Osti	Comparative Efficacy of Lenvatinib Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Meta-Analysis of Meta-Analyses
2491	ORAL PRESENTATION 17	23 April 2026, Thursday	18:30 - 20:00	Hasmik Ghazinyan	Hepatocellular Carcinoma in Armenia: Liquid Biopsies and Primary Assessment of Molecular Alterations Prevalence
2572	ORAL PRESENTATION 17	23 April 2026, Thursday	18:30 - 20:00	Xuanxuan Duan	Short-Course Adjuvant Tislelizumab plus Tyrosine Kinase Inhibitor Following Curative Ablation for Early-Stage Hepatocellular Carcinoma: A Prospective Cohort Study
2579	ORAL PRESENTATION 17	23 April 2026, Thursday	18:30 - 20:00	Liren Zhang	YTHDF1high cancer-associated fibroblasts-derived kynurenine promotes tumor progression by supplying an immunosuppressive niche
2627	ORAL PRESENTATION 17	23 April 2026, Thursday	18:30 - 20:00	Wang Hao	ZIP1⁺ CAFs Shape the Immunosuppressive Microenvironment to Drive Hepatocellular Carcinoma Progression
2644	ORAL PRESENTATION 17	23 April 2026, Thursday	18:30 - 20:00	Liu Jiangxi	FKBP10⁺ CAFs Shape the Immunosuppressive Microenvironment to Drive Hepatocellular Carcinoma Progression
1158	ORAL PRESENTATION 18	23 April 2026, Thursday	18:30 - 20:00	Mohamad Jamalina	Donor Isolated Hyperbilirubinemia and Post-Liver Transplant Survival: A Propensity-Matched Analysis
1162	ORAL PRESENTATION 18	23 April 2026, Thursday	18:30 - 20:00	Xianzhang Luo	Study on the Mechanism of Samhd1 Mediated NEMO Polyubiquitination in Liver Ischemia-Reperfusion Injury
1164	ORAL PRESENTATION 18	23 April 2026, Thursday	18:30 - 20:00	Zhenghua Luo	Study on the Mechanism of TRIM55 Mediating K63 Polyubiquitination of Bcl10 Protein to Aggravate Liver Ischemia-Reperfusion Injury
1167	ORAL PRESENTATION 18	23 April 2026, Thursday	18:30 - 20:00	Penghong Song	SERPINE2 mitigates hepatic ischemia-reperfusion injury via a SUMO-ubiquitin rheostat
1174	ORAL PRESENTATION 18	23 April 2026, Thursday	18:30 - 20:00	Qingyun Xie	A Ten-Year Comparative Analysis of Open vs. Laparoscopic Anatomical Hepatectomy for Right-Sided Complex Hepatocellular Carcinoma: A Large-Sample, Nationwide Multicenter Real-World Study
1237	ORAL PRESENTATION 18	23 April 2026, Thursday	18:30 - 20:00	‪Ekram Hasanin‪‏	Novel Trends in Liver Transplantation for MASLD and ALD: Emerging Epidemiology, Allocation & Post-Transplant Challenges
1243	ORAL PRESENTATION 18	23 April 2026, Thursday	18:30 - 20:00	Seyed Mohammad Amin Dashti	Liver Transplantation Outcomes in Primary Sclerosing Cholangitis Patients With and Without Ulcerative Colitis: A Comparative Analysis
1598	ORAL PRESENTATION 18	23 April 2026, Thursday	18:30 - 20:00	Zehra Ikbal Karabal	Pneumonia incidence and pathogen spectrum in liver transplant recipients: a decade-long retrospective analysis comparing pre-coronavirus disease 2019 and pandemic-era temporal patterns and risk factors
1846	ORAL PRESENTATION 18	23 April 2026, Thursday	18:30 - 20:00	Zulihumaer Aizimuaji	Patient-Derived Liver Organoids as a Translational Platform to Validate Targeted Nanoparticles for Image-Guided Liver Cancer Surgery
1176	ORAL PRESENTATION 19	23 April 2026, Thursday	18:30 - 20:00	Guixin Li	METTL16 drives MAFLD progression by regulating lipid synthesis and immune responses
1209	ORAL PRESENTATION 19	23 April 2026, Thursday	18:30 - 20:00	Feixiang Xiong	Therapeutic Effects of Qinggan Huatan Huoxue Prescription on Metabolic Dysfunction-Associated Steatohepatitis via Modulation of the CYP4a32-PPARγ-CD36 Signaling Axis
1226	ORAL PRESENTATION 19	23 April 2026, Thursday	18:30 - 20:00	Carolyn Wallace	Metabolic dysfunction-associated steatotic liver disease by fibrosis stage in China and Japan: a 20-year model
1250	ORAL PRESENTATION 19	23 April 2026, Thursday	18:30 - 20:00	Jie Liu	Identifying MASLD Patients with MASH or Significant Fibrosis : The Role of Lower ALT Thresholds
1265	ORAL PRESENTATION 19	23 April 2026, Thursday	18:30 - 20:00	Chen-Te Huang	Risk factors for advanced liver fibrosis in psoriasis patients with metabolic dysfunction-associated steatotic liver disease (MASLD)
1281	ORAL PRESENTATION 19	23 April 2026, Thursday	18:30 - 20:00	Katelyn Chiu	Short-Term Gains, Long-Term Challenges: A Pilot Randomized Controlled Trial for Time-Restricted Feeding Versus Caloric Restriction in Significant MASLD
1284	ORAL PRESENTATION 19	23 April 2026, Thursday	18:30 - 20:00	Hirokazu Takahashi	Antifibrotic Efficacy and Renal Safety of Pemafibrate in MASLD: A Multicenter Randomized Controlled Study
1286	ORAL PRESENTATION 19	23 April 2026, Thursday	18:30 - 20:00	Akio Moriya	Clinical characteristics of diabetic patients with limited improvement in elevated ALT following tirzepatide initiation
1334	ORAL PRESENTATION 19	23 April 2026, Thursday	18:30 - 20:00	Katelyn Chiu	Time-Restricted Feeding Improves Hepatic Fibrosis in Advanced MASLD: Preliminary Results from a Randomised Controlled Trial
1422	ORAL PRESENTATION 20	24 April 2026, Friday	07:30 - 09:00	Li Bai	Unveiling the pathogenesis and early warning biomarkers of acute liver failure associated with disulfidptosis through bioinformatics analysis and experimental validation
1426	ORAL PRESENTATION 20	24 April 2026, Friday	07:30 - 09:00	Xiao Che	Double plasma molecular adsorption system improves 90-day survival in patients with acute-on-chronic liver failure
1471	ORAL PRESENTATION 20	24 April 2026, Friday	07:30 - 09:00	Neha Sharma	Biomolecular Mapping of Circulating Extracellular Vesicles to Develop AI Driven Prognostic Panels for Stratifying Acute Liver Failure Patients at Risk of Early Mortality
1497	ORAL PRESENTATION 20	24 April 2026, Friday	07:30 - 09:00	Liang Peng	A Phase I Clinical Trial Evaluating the Safety and Efficacy of the QH-1A Combination Bio-artificial Liver Support System Incorporating Ex-vivo Mesenchymal Stem Cells for the Treatment of ACLF patients
1834	ORAL PRESENTATION 20	24 April 2026, Friday	07:30 - 09:00	Rungfah Saehan	The national burden of acute liver failure from 2019 to 2022: A Thailand nationwide population-based cross-sectional time series study
1857	ORAL PRESENTATION 20	24 April 2026, Friday	07:30 - 09:00	Alfiyyah Rizqy	Therapeutic Role of N-Acetylcysteine in Acute Liver Failure Secondary to Anti-Tuberculosis Drug-Induced Liver Injury: Insights From Indonesia
1895	ORAL PRESENTATION 20	24 April 2026, Friday	07:30 - 09:00	Yufei Bi	Add on traditional Chinese medicine for hospitalized acute on chronic liver disease
1943	ORAL PRESENTATION 20	24 April 2026, Friday	07:30 - 09:00	Seydanur Avci	Investigation of the Therapeutic Effects of β3-Adrenergic Stimulation on Paracetamol-Induced Acute Liver Damage
1950	ORAL PRESENTATION 20	24 April 2026, Friday	07:30 - 09:00	Chen Zhou	Decellularized Liver Matrix from Healthy versus Acute Liver Failure Livers Possesses Distinct Structural and Functional Properties
1486	ORAL PRESENTATION 21	24 April 2026, Friday	07:30 - 09:00	Yanpei Mai	Serum bile acids profile analysis predicts severity and progression of liver disease
1573	ORAL PRESENTATION 21	24 April 2026, Friday	07:30 - 09:00	A B M Shakil Gani	Comparison of ALBI, PALBI, MELD, and Child-Pugh Scores in Chronic Liver Disease: Evidence from Bangladesh
1649	ORAL PRESENTATION 21	24 April 2026, Friday	07:30 - 09:00	ZANNATUL HABIBA	Platelet-Albumin-Bilirubin (PALBI) Score: A non-invasive Predictor of Esophageal Varices in Patients with Liver Cirrhosis Compared to Child-Turcotte-Pugh (CTP) Score
2320	ORAL PRESENTATION 21	24 April 2026, Friday	07:30 - 09:00	Jaswinder Maras	Liver meta-proteome and kinome reveal Pseudomonas aeruginosa -pKCCη axis as a driver of steroid resistance in severe alcohol related hepatitis
2375	ORAL PRESENTATION 21	24 April 2026, Friday	07:30 - 09:00	Zhiying He	Achieving Recompensation with Low-dose Diuretics in HBV-related Cirrhosis: An Expanded Baveno VII Strategy Yields Similar Long-Term Prognosis in A Multicenter Cohort Study
2422	ORAL PRESENTATION 21	24 April 2026, Friday	07:30 - 09:00	Yrah Damiene Fernandez	Diagnostic Accuracy of Portal System Duplex Sonography Findings Among Filipinos with and Without Liver Cirrhosis; The DupLiCs Study




35TH ANNUAL MEETING OF THE ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER
22-25 April 2026
Istanbul Lütfi Kırdar International Convention and Exhibition Centre • İstanbul / Türkiye
www.apasi2026istanbul.org



Abstract No	Session Name	Session Date	Session Time	Presenter Name	Presentation Title
2438	ORAL PRESENTATION 21	24 April 2026, Friday	07:30 - 09:00	ANKUR JINDAL	Long-term Serial Liver Stiffness Monitoring, Histological Fibrosis, and HVPG as Determinants of Disease Progression and Decompensation in MASLD
2441	ORAL PRESENTATION 21	24 April 2026, Friday	07:30 - 09:00	Nipun Verma	MACHINE-LEARNING MODELS IMPROVES MORTALITY AND ANTIMICROBIAL RESISTANCE PREDICTION IN CULTURE-PROVEN SPONTANEOUS BACTERIAL PERITONITIS IN CIRRHOSIS: A MULTICENTER COHORT STUDY
2484	ORAL PRESENTATION 21	24 April 2026, Friday	07:30 - 09:00	Yanna Liu	CT-based Vasomics model for noninvasive diagnosis of Porto-sinusoidal vascular disease in patients with portal hypertension
1037	ORAL PRESENTATION 22	24 April 2026, Friday	07:30 - 09:00	Mengyi Shen	Engineered Vesicle-Mediated Metabolic Regulation and Immune Targeting for the Treatment of Autoimmune Hepatitis
1233	ORAL PRESENTATION 22	24 April 2026, Friday	07:30 - 09:00	Li Zhang	Predictors of response to ursodeoxycholic acid treatment and non-invasive identification of autoimmune hepatitis tendencies in primary biliary cholangitis
2353	ORAL PRESENTATION 22	24 April 2026, Friday	07:30 - 09:00	Erdi Şeker	Analysis of Aggressive Phenotypes in Hepatocellular Carcinoma Using Transcriptomic Data: A Machine Learning Framework for Biological Signature Discovery
2496	ORAL PRESENTATION 22	24 April 2026, Friday	07:30 - 09:00	Arjun Maria	Development and validation of an artificial intelligence driven convolutional neural network for automated stool colour classification to facilitate early diagnosis of biliary atresia
2583	ORAL PRESENTATION 22	24 April 2026, Friday	07:30 - 09:00	Zhuoru Jiang	Head-to-Head Comparison Between MRI and A Novel Portable VCTE Device (Liverscan): A Pilot Study
2639	ORAL PRESENTATION 22	24 April 2026, Friday	07:30 - 09:00	Harsh Vardhan Tevethia Tevethia	Machine learning(ML) based models predict beta-blocker response using non-invasive tests(NITs) in patients with acute variceal bleed -BE-RESPONSE STUDY
2851	ORAL PRESENTATION 22	24 April 2026, Friday	07:30 - 09:00	Sümeyye AĞIR	From Synthetic to Clinical: The Effect of Domain Shift on Decision Support Systems
2860	ORAL PRESENTATION 22	24 April 2026, Friday	07:30 - 09:00	YAO YUNLONG	Advances in Artificial Intelligence for Liver Disease Research: Algorithmic Applications and Technical Challenges
2881	ORAL PRESENTATION 22	24 April 2026, Friday	07:30 - 09:00	Bo WANG	Impact of an AI-Supported Triage System on the Diagnostic Workflow of Focal Pancreatic Lesions: A Real-World Clinical Utility Analysis
1103	ORAL PRESENTATION 23	24 April 2026, Friday	07:30 - 09:00	Yusuf Bunyamin Ketenci	Unusual Partners in Anemia: Zieve’s Syndrome and Beta-Thalassemia Trait in a Single Patient: A case report and literature review
1117	ORAL PRESENTATION 23	24 April 2026, Friday	07:30 - 09:00	Yun-Chieh Su	ADH1B rs6850217 as a Novel Genetic Determinant of Hepatocellular Carcinoma Risk in Chronic Hepatitis B
1215	ORAL PRESENTATION 23	24 April 2026, Friday	07:30 - 09:00	GAURAV TRIPATHI	Oxysterol-Binding Protein-Related Protein 2 Drives Sterol Accumulation and Neutrophil Dysfunction in Sepsis Associated with Alcoholic Cirrhosis
1310	ORAL PRESENTATION 23	24 April 2026, Friday	07:30 - 09:00	Xianwei Liu	Creb1-regulated slc39a1 attenuates alcoholic liver disease by orchestrating autophagy and mitophagy
1350	ORAL PRESENTATION 23	24 April 2026, Friday	07:30 - 09:00	Jiarui Zheng	Metabolic Syndrome is Independently Associated with 1-Year Readmission of Patients with Alcohol-Associated Cirrhosis
2443	ORAL PRESENTATION 23	24 April 2026, Friday	07:30 - 09:00	Aditya Soni	Histological severity is not associated with clinical presentation or outcome in children with autoimmune hepatitis
2681	ORAL PRESENTATION 23	24 April 2026, Friday	07:30 - 09:00	Lili zhao	Characteristics of Autoimmune Hepatitis in elderly patients
2700	ORAL PRESENTATION 23	24 April 2026, Friday	07:30 - 09:00	Ayse Sena Oguz	Does Primary Biliary Cholangitis and Autoimmune Hepatitis Increase the Risk of Precancerous Colon Polyps?
2760	ORAL PRESENTATION 23	24 April 2026, Friday	07:30 - 09:00	Astrid Amador	Real-world Biochemical Responses to First-line Azathioprine versus Mycophenolate and Upon Switching from Azathioprine to Mycophenolate in Autoimmune Hepatitis Patients
1903	ORAL PRESENTATION 24	24 April 2026, Friday	07:30 - 09:00	Rafael Emmanuel Mendoza	Performance of FIB-4 and MAFLD Fibrosis Score vs. Transient Elastography in a Filipino Cohort
1968	ORAL PRESENTATION 24	24 April 2026, Friday	07:30 - 09:00	Elif Cadirci	Investigation of the Effects of Vasopressin V2 Receptor Inhibition on Aquaporin Expression and Liver Functions in Sepsis-Induced Hepatic Injury
2068	ORAL PRESENTATION 24	24 April 2026, Friday	07:30 - 09:00	Ruixuan Hong	The impact of implementing the expanded antiviral therapy eligibility for HBsAg-positive pregnant women in China: a modelling study
2132	ORAL PRESENTATION 24	24 April 2026, Friday	07:30 - 09:00	Ajeet Singh Bhadoria	Leveraging Decentralization, Integration, and Task-Shifting to achieve Micro-elimination of Hepatitis C among prisoners in Northern India
2296	ORAL PRESENTATION 24	24 April 2026, Friday	07:30 - 09:00	Mohamed Abd Allah	From Campaign to Validation: Operationalizing Egypt’s National Sustainability Plan for Viral Hepatitis Elimination (2025–2030)
2318	ORAL PRESENTATION 24	24 April 2026, Friday	07:30 - 09:00	Manisha Yadav	Gut Microbiota Transfer and Integrated Omics Identify Streptococcal Collagen-Like (Scl1) Protein as a key fibrogenic driver in Alcohol associated liver disease.
2350	ORAL PRESENTATION 24	24 April 2026, Friday	07:30 - 09:00	Shiwen Ma	Generation of Macro-Scale Engineered Biliary Trees with P-gp Efflux Function and Enhanced Injury Resistance
2360	ORAL PRESENTATION 24	24 April 2026, Friday	07:30 - 09:00	Neslihan Başgöz Karaguş	Amlodipine activates an adaptive endoplasmic reticulum stress response in Huh-7 hepatocellular carcinoma cells
2361	ORAL PRESENTATION 24	24 April 2026, Friday	07:30 - 09:00	Ahmet Ozan Kaleci	L-canavanine selectively inhibits hepatocellular carcinoma cell proliferation and induces apoptosis in vitro
1824	ORAL PRESENTATION 25	24 April 2026, Friday	07:30 - 09:00	NIVEDITA NIVEDITA	Utility of EUS-guided Liver Biopsy in Liver Disease.
1923	ORAL PRESENTATION 25	24 April 2026, Friday	07:30 - 09:00	Wenjing Wang	Women's Perspective on Non-Antibiotic Interventions for rUTI Prevention: Meta-Analysis of Efficacy, Safety, and Clinical Implications
2244	ORAL PRESENTATION 25	24 April 2026, Friday	07:30 - 09:00	Rajit Gilhotra	Early Experience with Endoscopic Ultrasound-Guided Gastric Variceal Obliteration at an Australian Quaternary Referral Centre
2427	ORAL PRESENTATION 25	24 April 2026, Friday	07:30 - 09:00	Arka De	Endoscopic Ultrasound-Guided Portosystemic Pressure Gradient Measurement To Determine Candidacy For Simultaneous Liver-Kidney Transplantation Vs Renal Transplant Alone In End-Stage Renal Disease Patients With Compensated Advanced Chronic Liver Disease or Cirrhosis
2432	ORAL PRESENTATION 25	24 April 2026, Friday	07:30 - 09:00	Arpit Shastri	Endoscopic Ultrasound Guided Ablative Therapies For Hepatocellular Carcinoma
2483	ORAL PRESENTATION 25	24 April 2026, Friday	07:30 - 09:00	Yanan Sun	Endoscopic treatment for esophagogastric variceal bleeding in acute-on-chronic liver failure patients
2519	ORAL PRESENTATION 25	24 April 2026, Friday	07:30 - 09:00	Sercan Kiremitci	The long term results of EUS guided coil application for fundal varices
2553	ORAL PRESENTATION 25	24 April 2026, Friday	07:30 - 09:00	Hakan Şentürk	EUS guided liver biopsy for diffuse liver diseases is an emerging alternative to percutaneous liver biopsy
1007	ORAL PRESENTATION 26	24 April 2026, Friday	07:30 - 09:00	Atteyat A. Semeya	Direct-Acting Antiviral Therapy Reduces Variceal Rebleeding and Improves Liver Function in HCV-Related Cirrhosis: A Multicenter Retrospective Study in Egypt
1011	ORAL PRESENTATION 26	24 April 2026, Friday	07:30 - 09:00	Arailym Maikenova	Predictors of non-response to antiviral therapy for hepatitis C in Almaty, the largest city of Kazakhstan
1013	ORAL PRESENTATION 26	24 April 2026, Friday	07:30 - 09:00	Yuan Liu	Non-invasive prediction of hepatic inflammation grade in chronic hepatitis B patients based on multiple parameters non-enhancement MRI combined with clinical characteristics
1029	ORAL PRESENTATION 26	24 April 2026, Friday	07:30 - 09:00	Changle Wu	Global burden of hepatitis A virus 1990–2023: results from the Global Burden of Disease Study 2023
1045	ORAL PRESENTATION 26	24 April 2026, Friday	07:30 - 09:00	Tugba Sari	The Denizli Model: A Leading Strategy in the War on Hepatitis C
1076	ORAL PRESENTATION 26	24 April 2026, Friday	07:30 - 09:00	I Wayan Rendi Awendika	Optimizing Risk Stratification of Esophageal Varices for Endoscopic Surveillance: Diagnostic Value of APRI, FIB-4, King, and Bonacini Scores in Hepatitis-Related Liver Disease
1098	ORAL PRESENTATION 26	24 April 2026, Friday	07:30 - 09:00	Grace Wong	Disease burden of chronic hepatitis D virus (HDV) infection among people living with chronic hepatitis B virus (HBV) infection in a low-endemic city
1423	ORAL PRESENTATION 26	24 April 2026, Friday	07:30 - 09:00	Myriam Drysdale	Characterisation of people living with chronic hepatitis B virus infection in China and stratification by HBsAg levels
1436	ORAL PRESENTATION 26	24 April 2026, Friday	07:30 - 09:00	Yi Wang	HBV Inhibits Stress Granule Formation by Hijacking SG Core Proteins into the Nucleocapsids
1195	ORAL PRESENTATION 27	24 April 2026, Friday	07:30 - 09:00	Jia Liu Liu	MMP-9 Suppresses the Anti-HBsAg B Cell Response During Chronic HBV Infection
1305	ORAL PRESENTATION 27	24 April 2026, Friday	07:30 - 09:00	Yansheng Liu	Fenofibrate and ursodeoxycholic acid in treatment-naïve primary biliary cholangitis: a pilot randomized trial with integrated multi-omics analysis
1542	ORAL PRESENTATION 27	24 April 2026, Friday	07:30 - 09:00	Qi Wang	Mechanistic Insights into the Protective Effects of Faecalibacterium prausnitzii and Its Metabolite Short Chain Fatty Acids on Biliary Injury in Primary Biliary Cholangitis
1798	ORAL PRESENTATION 27	24 April 2026, Friday	07:30 - 09:00	Atsushi Tanaka	East Asian subgroup analysis of the global Phase 3 GLISTEN study of linciclib for the treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC)
1938	ORAL PRESENTATION 27	24 April 2026, Friday	07:30 - 09:00	İkram aluahabi	Prediction of Esophageal Varices in Primary Biliary Cholangitis: What Is the Role of Non-Invasive Tests?
2793	ORAL PRESENTATION 27	24 April 2026, Friday	07:30 - 09:00	Yanchen Ma	4-1BB Costimulation Restore Tfh1 Function to Augment HBV-Specific Humoral Immunity in Chronic Infection
2796	ORAL PRESENTATION 27	24 April 2026, Friday	07:30 - 09:00	Shihong Zhong	Interferon-β945; programs HBsAg-specific humoral immunity through the monocyte-IL6-Tfh cell axis to facilitate functional cure of hepatitis B
2818	ORAL PRESENTATION 27	24 April 2026, Friday	07:30 - 09:00	Emilia Krasavina	Updated results of the observational study to assess virological effectiveness, safety, and tolerability of NVR/RTV+SOF combination in HCV infected people living with HIV
2888	ORAL PRESENTATION 27	24 April 2026, Friday	07:30 - 09:00	Munira Jahan Jahan	Evaluation of selected Plasma Long Non-Coding RNAs as predictive Biomarkers in HBV-Related Hepatocellular Carcinoma
1328	ORAL PRESENTATION 28	24 April 2026, Friday	07:30 - 09:00	Hiba Al Lawati	CRISPR Prime Targeting of Interleukin 1 Receptor Type 1 (IL1r1) in Stellate Cells Identifies a Pathogenic Inflammation-to-Fibrosis Axis in the Liver
1361	ORAL PRESENTATION 28	24 April 2026, Friday	07:30 - 09:00	Swarup Sasidharan	L-Taurine for Fatigue in Decompensated Cirrhosis: A Randomized Controlled Trial
1377	ORAL PRESENTATION 28	24 April 2026, Friday	07:30 - 09:00	Yanhua Chen	Computed tomography-based sarcopenic obesity can predict cardiovascular and cerebrovascular mortality in patients with cirrhosis
1389	ORAL PRESENTATION 28	24 April 2026, Friday	07:30 - 09:00	M Golam Azam Azam MG	Variability of Presentation of Cholelithiasis in Relation to Etiology and Stages of Cirrhosis of Liver in a Tertiary Care Hospital in Dhaka City
1408	ORAL PRESENTATION 28	24 April 2026, Friday	07:30 - 09:00	Yuwei Wang	Predicting Recompensation and Exploring the Prognostic Benefit of its Durability in patients with HBV-related decompensated cirrhosis
1419	ORAL PRESENTATION 28	24 April 2026, Friday	07:30 - 09:00	Zongyi Liu	Evodiamine alleviates liver fibrosis by targeting the ANXA2/PI3K/AKT/CCND1 axis in hepatic stellate cells




35TH ANNUAL MEETING OF THE ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER
22-25 April 2026
Istanbul Lütfi Kırdar International Convention and Exhibition Centre • İstanbul / Türkiye
www.apasi2026istanbul.org



Abstract No	Session Name	Session Date	Session Time	Presenter Name	Presentation Title
1507	ORAL PRESENTATION 28	24 April 2026, Friday	07:30 - 09:00	Maria Nadinskaia	Hyperammonemia in pre-hepatic and intrahepatic portal hypertension: comparable levels, different clinical outcomes
1551	ORAL PRESENTATION 28	24 April 2026, Friday	07:30 - 09:00	Mohamed Abdel-Samiee	Non Invasive Detection of Esophageal Varices in Compensated Cirrhotic Patients
1568	ORAL PRESENTATION 28	24 April 2026, Friday	07:30 - 09:00	Bingqing Yang	Role of CD146-High Endothelial Cells in Vascular Remodeling and Fibrosis Progression in Cirrhotic Liver: A Single-Cell Transcriptomic Study
1527	ORAL PRESENTATION 29	24 April 2026, Friday	10:50 - 12:10	RuoChan Chen	Development and Validation of an Early Diagnostic Model to Distinguish Bacterial Infection in Patients with Acute-on-Chronic Liver Disease (AoCLD) and Systemic Inflammatory Response Syndrome (SIRS)
1531	ORAL PRESENTATION 29	24 April 2026, Friday	10:50 - 12:10	Demin Yu	Dynamic changes in gut microbiota associated with HBsAg decline in chronic hepatitis B patients undergoing IFN treatment
1533	ORAL PRESENTATION 29	24 April 2026, Friday	10:50 - 12:10	Qiao Tang	Sex differences in cirrhosis among untreated chronic hepatitis B: a 10-year longitudinal cohort study from China
1555	ORAL PRESENTATION 29	24 April 2026, Friday	10:50 - 12:10	Elif Nur Özbay Haliloğlu	Concordance Between Ultrasound Steatosis Grading and Elastography-CAP Classification: A Case Series of Chronic HBV Patients on TAF Therapy
1560	ORAL PRESENTATION 29	24 April 2026, Friday	10:50 - 12:10	Dr Arifa Tasnim	Correlation between transient elastography and liver biopsy in CHB patients with elevated HBV DNA with normal ALT
1565	ORAL PRESENTATION 29	24 April 2026, Friday	10:50 - 12:10	Qiuju Sheng	The Efficacy and Safety of Pegylated Interferon Alpha Treatment in Patients with HBV Related Cirrhosis and HCC after Radical Surgery (1 Year Data from the TERMINATOR Project)
1567	ORAL PRESENTATION 29	24 April 2026, Friday	10:50 - 12:10	Conglin Zhao	Multi-omics Analysis of Bile Acid Dysregulation in Hepatitis E virus Infection
1589	ORAL PRESENTATION 29	24 April 2026, Friday	10:50 - 12:10	Yanjie Lin	Intermittent therapy restores anti-HBV efficacy of IFN by reducing elevated dysfunctional HLA-DR+CD38hiCD8+ T lymphocytes
1602	ORAL PRESENTATION 29	24 April 2026, Friday	10:50 - 12:10	Xuejie Zhang	The Association Analysis of Metabolic Comorbidities and the 10-Year Prognosis of Hepatic Events in Chronic Hepatitis B Patients
2137	ORAL PRESENTATION 30	24 April 2026, Friday	10:50 - 12:10	Dr. Aftab Abbasi	Protective and Therapeutic Roles of Vitamin D in Reducing Chlorpyrifos Induced Liver Fibrosis Through Modulation of Fibrotic Pathways
2188	ORAL PRESENTATION 30	24 April 2026, Friday	10:50 - 12:10	Gamal Shiha	Personalised Risk-Based HCC Surveillance in HCV-Related Advanced Fibrosis/Cirrhosis After SVR: Real-World Evidence of Cost Effectiveness.
2201	ORAL PRESENTATION 30	24 April 2026, Friday	10:50 - 12:10	Murat Taner GÜLŞEN	Prospective Evaluation of Factors Affecting Measurement Quality in Liver Elastography
2226	ORAL PRESENTATION 30	24 April 2026, Friday	10:50 - 12:10	Javaria Younas Muhammad Younas	Impact of Diabetes on Fibrosis Progression in NAFLD: A Systematic Review and Meta-analysis
2302	ORAL PRESENTATION 30	24 April 2026, Friday	10:50 - 12:10	Shuntaro Obi	Stiffness Regression Fundamentally Alters Mortality Patterns and Improves Survival in Advanced Fibrosis After SVR: A Cause-Specific Outcome Analysis
2309	ORAL PRESENTATION 30	24 April 2026, Friday	10:50 - 12:10	Thi Thanh Thuy Le	Zonal Restoration and Inter-Cellular Signaling in Fibrosis Regression: Single-Cell Transcriptomics Decodes the Pericentral Hepatocyte-HSC Axis
2311	ORAL PRESENTATION 30	24 April 2026, Friday	10:50 - 12:10	Xuzhen Yan	LOXL1 Regulates Lipid Metabolism to Promote Hepatic Stellate Cell Activation via Ubiquitin-Mediated FASN Degradation
2349	ORAL PRESENTATION 30	24 April 2026, Friday	10:50 - 12:10	Xuemei WANG	Study on the Anti-Liver Cirrhosis of Luteolin: Targeting the PPARα Axis to Regulate Macrophage Fatty Acid Metabolic Reprogramming
2369	ORAL PRESENTATION 30	24 April 2026, Friday	10:50 - 12:10	Fei Wang	AGIUS Score Predicts Re-bleeding Risk after Endoscopic Variceal Ligation in Cirrhotic Patients Introduction
1280	ORAL PRESENTATION 31	24 April 2026, Friday	10:50 - 12:10	Jia-Yong Su	Tislelizumab plus lenvatinib versus tislelizumab monotherapy as adjuvant therapy for hepatocellular carcinoma patients at high risk of recurrence : a prospective, multicenter cohort study
1308	ORAL PRESENTATION 31	24 April 2026, Friday	10:50 - 12:10	Wenyong Qiao	KDM5A-Driven Epigenetic Reprogramming of IL1B⁺ CD14⁺ Monocytes Mediates Resistance to Anti-PD-1 Therapy in Advanced Hepatocellular Carcinoma by Suppressing T Cell-Mediated Antitumor Immunity
1326	ORAL PRESENTATION 31	24 April 2026, Friday	10:50 - 12:10	Irene Oi-Lin Ng	Repurposing Resmetromir suppresses MASH-associated hepatocellular carcinoma and mechanistic implications of MDK/LRP1-mediated metabolic reprogramming and immunosuppression
1349	ORAL PRESENTATION 31	24 April 2026, Friday	10:50 - 12:10	Van Trung Huynh	Enhanced detection of hepatocellular carcinoma using combined biomarker panels including alpha-fetoprotein, alpha-fetoprotein-L3, des-gamma-carboxyprothrombin and the galad score
1393	ORAL PRESENTATION 31	24 April 2026, Friday	10:50 - 12:10	Da-Long Yang	Optimal timing of hepatectomy after conversion therapy and stratification by risk of recurrence in patients with hepatocellular carcinoma: a multicenter retrospective investigation (GUIDANCE005)
1396	ORAL PRESENTATION 31	24 April 2026, Friday	10:50 - 12:10	RAJAT PRABHAKAR PANDE	Exploring the efficacy of Systemic Inflammatory Markers in predicting outcomes post Transarterial Chemoembolization (c TACE & deb TACE)
1416	ORAL PRESENTATION 31	24 April 2026, Friday	10:50 - 12:10	Peng Chen	PPARα Activation Restores GSDME Pyroptosis to Reverse Anti-PD-1 Resistance in HCC
1463	ORAL PRESENTATION 31	24 April 2026, Friday	10:50 - 12:10	Yuta Maruki	Real-World Outcomes of Durvalumab Plus Tremelimumab (STRIDE) for Unresectable Hepatocellular Carcinoma in Japanese Patients
1468	ORAL PRESENTATION 31	24 April 2026, Friday	10:50 - 12:10	Jian-Hong Zhong	Multicenter evaluation of the efficacy and safety of rechallenge with immune checkpoint inhibitors in unresectable hepatocellular carcinoma
2150	ORAL PRESENTATION 32	24 April 2026, Friday	10:50 - 12:10	Asahiro Morishita	Early Skeletal Muscle Loss Predicts Poor Outcomes in Advanced Hepatocellular Carcinoma Treated with Hepatic Arterial Infusion Chemotherapy
2161	ORAL PRESENTATION 32	24 April 2026, Friday	10:50 - 12:10	Xi Zhang	Circulating Tumor DNA Analysis Enables Early Detection of Hepatocellular Carcinoma in High-Risk Patients
2185	ORAL PRESENTATION 32	24 April 2026, Friday	10:50 - 12:10	KAI-WEN HUANG	Nonthermal Histotripsy Enables Complete Ablation of Perivascular Liver Tumors While Preserving Adjacent Vessel Patency
2215	ORAL PRESENTATION 32	24 April 2026, Friday	10:50 - 12:10	Ning Wang	Innovative Insights: Hepatic Stellate Cells activation and ROS-Gene Signatures Predicting Prognosis and Immunotherapy Response in Hepatocellular Carcinoma
2254	ORAL PRESENTATION 32	24 April 2026, Friday	10:50 - 12:10	Hiroki Tai	Prognostic Impact of Sarcopenia Assessed by Handgrip Strength and Skeletal Muscle Index in Hepatocellular Carcinoma Patients Receiving Atezolizumab plus Bevacizumab Therapy
2290	ORAL PRESENTATION 32	24 April 2026, Friday	10:50 - 12:10	Nitesh Kumar Karna	Coffee Consumption and Hepatocellular Carcinoma: An Umbrella Review of Meta-Analyses involving Over 12 Million Population
2291	ORAL PRESENTATION 32	24 April 2026, Friday	10:50 - 12:10	Wenxin Yan	The Antagonism between Demographic Shifts and Epidemiological Progress: A Decomposition Analysis of the Liver Cancer Burden in the Asia-Pacific, 1990-2023
2329	ORAL PRESENTATION 32	24 April 2026, Friday	10:50 - 12:10	Junjie Xu	Multi-omics analyses identify a novel hepatocellular carcinoma subtype with better response to immune checkpoint inhibitor therapies
2351	ORAL PRESENTATION 32	24 April 2026, Friday	10:50 - 12:10	Amarsanaa Jazag	A-HOC Study on Patients Under Real-time Surveillance for Liver Cancer in Mongolia
1006	ORAL PRESENTATION 33	24 April 2026, Friday	10:50 - 12:10	Jiahao Han	Ultrasound-derived Fat Fraction is a Reliable Method to Grade Hepatic Steatosis in Patients with Chronic Liver Diseases: A Multicenter Study in a Population with Mixed Etiologies
1056	ORAL PRESENTATION 33	24 April 2026, Friday	10:50 - 12:10	Eda Kaya	Development of a Predictive Formula for Hepatic Steatosis in Apparently Healthy Individuals: A Biopsy-Proven Study in Turkish Liver Transplant Donors
2386	ORAL PRESENTATION 33	24 April 2026, Friday	10:50 - 12:10	Anh Nguyen Thi Van	Immunosuppressive Medication Non-adherence in Liver Transplantation Adult Recipients in Vietnam
2504	ORAL PRESENTATION 33	24 April 2026, Friday	10:50 - 12:10	Devrim Muge Ozari Gulnar	Long-term outcomes of patients with Hepatitis D recurrence after liver transplantation
2577	ORAL PRESENTATION 33	24 April 2026, Friday	10:50 - 12:10	Yunzhi Shen	Using Rose to Improve the Accuracy of Diagnosis of Biliary Tract Diseases through ERCP guided Biopsy
2695	ORAL PRESENTATION 33	24 April 2026, Friday	10:50 - 12:10	Adem Kose	Candidemia in Liver Transplant Recipients: A Ten-Year Retrospective Study
2699	ORAL PRESENTATION 33	24 April 2026, Friday	10:50 - 12:10	emre aray	RAPID Procedure Enables Safe Use of Small Left Lobe Grafts: A Two-Center Experience
2904	ORAL PRESENTATION 33	24 April 2026, Friday	10:50 - 12:10	Jinzheng Cai	Clinical Analysis of Liver Transplantation in Patients With Severe Liver Disease
2905	ORAL PRESENTATION 33	24 April 2026, Friday	10:50 - 12:10	Jinzheng Cai	A clinical study on the reduction of donor lymphocyte chimerism rate in recipient tissues after liver transplantation by extracorporeal perfusion of anti-thymocyte globulin via portal vein
2012	ORAL PRESENTATION 34	24 April 2026, Friday	18:30 - 20:00	Deliang Huang	Eliminating Viral Hepatitis by 2030: Goals and Gaps from a Large-Scale Community-Based Study in Shenzhen, China
2104	ORAL PRESENTATION 34	24 April 2026, Friday	18:30 - 20:00	Zhengzhao Lu	A Longer Way to Go: Chronic Hepatitis B Burden and Trends Across the Asian-Pacific Region
2105	ORAL PRESENTATION 34	24 April 2026, Friday	18:30 - 20:00	Shauna MADIGAN	Breaking the habit: Evaluating the routine use of SBP prophylaxis
2107	ORAL PRESENTATION 34	24 April 2026, Friday	18:30 - 20:00	Terry Cheuk-Fung Yip	COVID-19 pandemic had minimal impact on the diagnostic and treatment uptakes for HCV – a territory-wide study
2121	ORAL PRESENTATION 34	24 April 2026, Friday	18:30 - 20:00	Hassan Mahmood	Eliminating Viral Hepatitis in Pakistan: A Comprehensive Strategic Framework
2143	ORAL PRESENTATION 34	24 April 2026, Friday	18:30 - 20:00	Huma Qureshi	A model, screen test and treat hepatitis C elimination project among under-served communities in Islamabad the federal capital of Pakistan
2189	ORAL PRESENTATION 34	24 April 2026, Friday	18:30 - 20:00	Shanshan Zhu	HBsAg Dynamics and Seroclearance Maintenance After Interferon Cessation in Chronic Hepatitis B Patients
2229	ORAL PRESENTATION 34	24 April 2026, Friday	18:30 - 20:00	Shaohui Zhang	Discrepancies in the indeterminate phase in patients with chronic hepatitis B between two updated international guidelines
2240	ORAL PRESENTATION 34	24 April 2026, Friday	18:30 - 20:00	Imran Hasanoglu	Hepatitis B Management in Primary Care: Nationwide Survey Highlights Knowledge and Practice Gaps Among Family Physicians in Türkiye
1469	ORAL PRESENTATION 35	24 April 2026, Friday	18:30 - 20:00	Yulong Shang	Targeting NEK9 in hepatocellular carcinoma to remodel immune microenvironment and enhance immunotherapy
1473	ORAL PRESENTATION 35	24 April 2026, Friday	18:30 - 20:00	Dongbo Chen	Dominant Neoantigens in Liver Cancer Malignant Ascites
1493	ORAL PRESENTATION 35	24 April 2026, Friday	18:30 - 20:00	Lu Li	Clinical determinants of treatment response in Asian hepatocellular carcinoma undergoing lenvatinib therapy: the impact of non-viral liver disease etiologies
1516	ORAL PRESENTATION 35	24 April 2026, Friday	18:30 - 20:00	Satoshi Narahara	Serum HBP as a Mechanistic Predictor of Primary Resistance to Atezolizumab plus Bevacizumab in HCC.
1528	ORAL PRESENTATION 35	24 April 2026, Friday	18:30 - 20:00	Matthew Shing-Hin Chung	Palliative care reduces disease time burden but is under-utilized in terminal-stage hepatocellular carcinoma




**35TH ANNUAL MEETING OF THE ASIAN PACIFIC
ASSOCIATION FOR THE STUDY OF THE LIVER**
 22-25 April 2026
 Istanbul Lütfi Kırdar International Convention and Exhibition Centre • İstanbul / Türkiye
www.apasl2026istanbul.org



Abstract No	Session Name	Session Date	Session Time	Presenter Name	Presentation Title
1529	ORAL PRESENTATION 35	24 April 2026, Friday	18:30 - 20:00	Zhengnan Cao	CD39 Promotes Angiogenesis and Poor Prognosis in Hepatocellular Carcinoma via Activation of the PI3K/AKT Signaling Pathway
1552	ORAL PRESENTATION 35	24 April 2026, Friday	18:30 - 20:00	Fengna Yan	Multi-Omics Integration Identifies a Prognostic Signature Guiding Precision Survival in Advanced HCC
1564	ORAL PRESENTATION 35	24 April 2026, Friday	18:30 - 20:00	Takeshi Okamoto	Second-line Therapy after Immunotherapy for Unresectable Hepatocellular Carcinoma: a Multicenter Data Registry Analysis
1576	ORAL PRESENTATION 35	24 April 2026, Friday	18:30 - 20:00	Yilan Yang	Qilingxiaoji formula and the effective ingredients inhibit hepatocellular carcinoma progression by inhibiting miR32/GPR180 signaling pathway
2666	ORAL PRESENTATION 36	24 April 2026, Friday	18:30 - 20:00	Dali Zhang	Outcomes of cholangiocarcinoma (ICC) or combined hepatocellular-cholangiocarcinoma after liver transplantation
2678	ORAL PRESENTATION 36	24 April 2026, Friday	18:30 - 20:00	Xi He	HBV recurrence in patients with hepatocellular carcinoma and cholangiocarcinoma following liver transplantation
2679	ORAL PRESENTATION 36	24 April 2026, Friday	18:30 - 20:00	Dali Zhang	Outcomes of cholangiocarcinoma (ICC) or combined hepatocellular-cholangiocarcinoma after liver transplantation
2690	ORAL PRESENTATION 36	24 April 2026, Friday	18:30 - 20:00	Yuhao Su	TACE plus Lenvatinib and Envafoimab for Conversion Therapy in Unresectable HCC: A Prospective, Phase II Study
2739	ORAL PRESENTATION 36	24 April 2026, Friday	18:30 - 20:00	Xuhua Duan	D-TACE Combined with HAIC Versus D-TACE in BCLC Stage C HCC: A Randomized Controlled Trial
2753	ORAL PRESENTATION 36	24 April 2026, Friday	18:30 - 20:00	Gulzar Khan	Clinical and biochemical predictors of Hepatocellular Carcinoma: A Five-Year Cohort Study from a Tertiary Care Center in Pakistan
2756	ORAL PRESENTATION 36	24 April 2026, Friday	18:30 - 20:00	Hongli Yu	Locoregional Therapy Combined with Continuing or Switching Systemic Therapy for Intrahepatic Oligoprogression in Hepatocellular Carcinoma: A Multicenter Retrospective Study
2784	ORAL PRESENTATION 36	24 April 2026, Friday	18:30 - 20:00	Fuat Aksoy	The Effect of HALP Score on Predicting Post-Transplant Outcomes in Patients with Hepatocellular Carcinoma
2809	ORAL PRESENTATION 36	24 April 2026, Friday	18:30 - 20:00	Sati Coşkun Yazgan	Long-Term Survival in De Novo Liver-Metastatic Colorectal Cancer: A Descriptive Cohort Study
1337	ORAL PRESENTATION 37	24 April 2026, Friday	18:30 - 20:00	Qing Ye	Analysis of Factors Associated with Liver Fibrosis in Type 2 Diabetes Patients and the Predictive Value of CH13L1 for Liver Fibrosis
1352	ORAL PRESENTATION 37	24 April 2026, Friday	18:30 - 20:00	Dang Toan Vo	Evaluation of Liver Fibrosis Using FIB-4 and ARFI in Non-Diabetic NAFLD Patients
1401	ORAL PRESENTATION 37	24 April 2026, Friday	18:30 - 20:00	Mst. Rejina Afrin	Effects of the secondary metabolites of Terminalia arjuna on non-alcoholic fatty liver disease in experimental mice model
1417	ORAL PRESENTATION 37	24 April 2026, Friday	18:30 - 20:00	Takefumi Kimura	The Clarity Trial: Prospective evaluation of pemafibrate therapy in MASLD
1431	ORAL PRESENTATION 37	24 April 2026, Friday	18:30 - 20:00	Siru Wu	Persistent sarcopenia confers a cumulative risk of fibrosis progression and liver-related events in biopsy-proven metabolic dysfunction-associated fatty liver disease
1588	ORAL PRESENTATION 37	24 April 2026, Friday	18:30 - 20:00	Zheng Liu	Role and Mechanism of TGF-β/Smad Signaling in Regulating Hepatocyte-Macrophage Crosstalk in Metabolic Dysfunction-Associated Steatohepatitis
1609	ORAL PRESENTATION 37	24 April 2026, Friday	18:30 - 20:00	Yankun Gao	Prediction of Liver-Related Events Using Non-invasive Fibrosis Scores in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease
1615	ORAL PRESENTATION 37	24 April 2026, Friday	18:30 - 20:00	Yi Xu	Mechanistic Study of Celiac Sympathetic Denervation in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)
1629	ORAL PRESENTATION 37	24 April 2026, Friday	18:30 - 20:00	Ziyu Zhang	Analysis of Risk Factors and Establishment of a Predictive Model for Liver Disease Severity in Non-Alcoholic Fatty Liver Disease
2256	ORAL PRESENTATION 38	24 April 2026, Friday	18:30 - 20:00	Hafsa Abdul Waheed Jadgeal	Efficacy of Combined Nutritional and Physical Activity Intervention in Reversing Early MAFLD
2297	ORAL PRESENTATION 38	24 April 2026, Friday	18:30 - 20:00	Kubra Koken	Ischemia-Modified Albumin in MASLD: Correlation With Ultrasonographic Steatosis Grade and Elastography-Based Liver Stiffness
2310	ORAL PRESENTATION 38	24 April 2026, Friday	18:30 - 20:00	Lei Zhao	NAFLD promotes early hepatocellular carcinoma recurrence via MDSC metabolic reprogramming: Insights from a two-phase recurrence model in mice
2328	ORAL PRESENTATION 38	24 April 2026, Friday	18:30 - 20:00	DESIREE JANE LACUIN	Fatty Liver as a Key Risk Modifier for Adenoma Detection in FIT-Positive Young Adults: A Systematic Review of the Available Evidence
2347	ORAL PRESENTATION 38	24 April 2026, Friday	18:30 - 20:00	Jacob George	Semaglutide demonstrates efficacy in improving liver fibrosis across diverse subpopulations in part 1 of the ESSENCE trial – outcomes in Asian and non-Asian populations
2374	ORAL PRESENTATION 38	24 April 2026, Friday	18:30 - 20:00	Abdulvahap Hohluoğlu	Non-Invasive Assessment of Steatosis and Stiffness in MASLD: Links to Body Composition and Dyslipidemia in High-Risk Metabolic Groups
2385	ORAL PRESENTATION 38	24 April 2026, Friday	18:30 - 20:00	Rui Jin	HECTD3 Mediates PRDX4 Stabilization via K63-Linked Ubiquitination to Ameliorate Hepatic Steatosis, Inflammation, and Fibrosis in MASH
2426	ORAL PRESENTATION 38	24 April 2026, Friday	18:30 - 20:00	Yixuan Zhu	Association of Immune Nutritional Status with Histological Stage and Mortality in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Population-Based Cohort Study
2559	ORAL PRESENTATION 38	24 April 2026, Friday	18:30 - 20:00	Chenlu Yang	Evaluation of a FIB-4-Based Clinical Pathway for Fibrosis Assessment in Patients with Coronary Heart Disease
2574	ORAL PRESENTATION 39	24 April 2026, Friday	18:30 - 20:00	Ammal Metwally	Plasma microRNA-based non-invasive stratification of clinically significant and advanced fibrosis in metabolic dysfunction-associated steatotic liver disease among Arab adults
2609	ORAL PRESENTATION 39	24 April 2026, Friday	18:30 - 20:00	Huiling Cao	Acetylation modification of PKM2 promotes macrophage reprogramming and accelerates the progression of MAFLD
2614	ORAL PRESENTATION 39	24 April 2026, Friday	18:30 - 20:00	Zhongji Meng	A Cross-Section Study on the Co-prevalence of MAFLD and HBV Infection Among Adult Residents in Maojian District, Shiyuan City.
2617	ORAL PRESENTATION 39	24 April 2026, Friday	18:30 - 20:00	Feihu Bai Bai Feihu	Spirulina Prevents Hepatic Steatosis by Promoting Macrophage M2 Polarization via Gut Microbiota-Derived 2-Hydroxy-3-Methylbutyrate
2620	ORAL PRESENTATION 39	24 April 2026, Friday	18:30 - 20:00	Daya Zhang Zhang Daya	The Gut Fungus Rhizopus microsporus var. rhizopodiformis Exacerbates Metabolic-associated Fatty Liver Disease by Impairing Intestinal Barrier Integrity
2623	ORAL PRESENTATION 39	24 April 2026, Friday	18:30 - 20:00	ZHU XIAONING	Transcriptomic Profiling Identifies Anti-Inflammatory and Anti-Steatotic Programs Mediated by ShenGe Formula in MAFLD
2626	ORAL PRESENTATION 39	24 April 2026, Friday	18:30 - 20:00	Chunyan Wang	Clinical characteristics of colorectal polyps in patients with non-alcoholic fatty liver disease in high altitude areas
2641	ORAL PRESENTATION 39	24 April 2026, Friday	18:30 - 20:00	Eman Fares	Prevalence of Metabolic-Associated Fatty Liver Disease in Patients with Rheumatoid Arthritis: A Cross-Sectional Study
2643	ORAL PRESENTATION 39	24 April 2026, Friday	18:30 - 20:00	Jiawei Cui	IL-24 attenuates hepatocyte apoptosis and ameliorates metabolic-associated steatohepatitis by activating the autophagy-lysosome pathway
1414	ORAL PRESENTATION 40	24 April 2026, Friday	18:30 - 20:00	Sanju Yadav	Multi-omics integration analysis identifies Molecular Signatures of Liver Stress in preclinical model of Acute Hypoxia
1484	ORAL PRESENTATION 40	24 April 2026, Friday	18:30 - 20:00	Ceylan KÜPELİ	Exploring the Anticancer Effects of Spirulina Extract in Human Hepatocellular Carcinoma Cells
1677	ORAL PRESENTATION 40	24 April 2026, Friday	18:30 - 20:00	Eman El-Ahwany	Establishment of the TBRI Biobank for Liver Diseases: Advancing Research Translation and Precision Medicine in Hepatology
1698	ORAL PRESENTATION 40	24 April 2026, Friday	18:30 - 20:00	rajaaboukhraiss	Etiological Predictors of Portal Vein Thrombosis in Patients with Porto-Sinusoidal Vascular Disease
1781	ORAL PRESENTATION 40	24 April 2026, Friday	18:30 - 20:00	Jiahao Yuan	An Endothelial-Related Gene Signature Derived from Integrative Transcriptomics Predicts HCC in Cirrhosis
1812	ORAL PRESENTATION 40	24 April 2026, Friday	18:30 - 20:00	Weihua Cao	Clinical characteristics and influencing factors of porto-sinusoidal vascular disease patients with metabolic dysfunction-associated steatotic liver disease
2815	ORAL PRESENTATION 40	24 April 2026, Friday	18:30 - 20:00	Nicholas Dunn	Associations Between Dietary recommendations/ diet quality and Steatotic Liver Disease Prevalence and Severity in U.S. Adults 2017–2023
2833	ORAL PRESENTATION 40	24 April 2026, Friday	18:30 - 20:00	Huilian Shi	Hyperinsulinemia Establishes a Pathogenic Feedback Loop between Pyroptotic Hepatocytes and MDSCs in MAFLD
2878	ORAL PRESENTATION 40	24 April 2026, Friday	18:30 - 20:00	Krisanto Tanjaya	From Stool to Personalized Screening Approach: A Comprehensive Meta-analysis of Metagenomic Gut Microbiota Assessment in Patient with MAFLD and Control Cohort
1159	ORAL PRESENTATION 41	24 April 2026, Friday	18:30 - 20:00	Lujie Liu	Gut Microbiota-Derived CoQ8 Improves Hepatic Lipid Metabolism via GPR120
2488	ORAL PRESENTATION 41	24 April 2026, Friday	18:30 - 20:00	Lajpat Rai	SAFETY OF MIDAZOLAM AND NALBUPHINE IN CIRRHOTIC PATIENTS WHO UNDERGO UPPER GASTROINTESTINAL ENDOSCOPY
2554	ORAL PRESENTATION 41	24 April 2026, Friday	18:30 - 20:00	Jayadevan K	A Preclinical study on Protective Effects of Atorvastatin Against Methotrexate-Induced Hepato-Renal Toxicity: Role of Oxidative Stress and Inflammation
2562	ORAL PRESENTATION 41	24 April 2026, Friday	18:30 - 20:00	Irshad Batool	Successful Endoscopic Ultrasound-Guided Ethanol Ablation of a 7-mm Non-Functional Pancreatic Neuroendocrine Tumor in a High-Risk Surgical Candidate
2634	ORAL PRESENTATION 41	24 April 2026, Friday	18:30 - 20:00	Yingying Nie	A Novel Murine Model of MetALD Recapitulates the Synergistic and Aggressive Phenotype of Combined Metabolic Dysfunction and Alcohol Consumption
2640	ORAL PRESENTATION 41	24 April 2026, Friday	18:30 - 20:00	Mehmet Demir	Necrolytic migratory erythema without glucagonoma: An unusual association with chronic pancreatitis and hepatic dysfunction
2733	ORAL PRESENTATION 41	24 April 2026, Friday	18:30 - 20:00	Runci Jiang	Joint Association of C-Reactive Protein and the Triglyceride Glucose-Chinese Visceral Adiposity Index with Incident Chronic Liver Disease: A National Cohort Study
2748	ORAL PRESENTATION 41	24 April 2026, Friday	18:30 - 20:00	Mario Rafael Estella	A Retrospective Cohort Study on the Adherence to American Association for the study of Liver Diseases (AASLD) Quality Measures in Cirrhosis for Variceal Bleeding and its Association with Clinical Outcomes
2848	ORAL PRESENTATION 41	24 April 2026, Friday	18:30 - 20:00	Hong-Li Liu	Physician-Patient Dual-Track Follow-Up Care Bundle in Hepatology: A Multidisciplinary Practice Model Integrating Clinical Care and Research Coordination
1954	ORAL PRESENTATION 42	25 April 2026, Saturday	07:30 - 09:00	Fatih Albayrak	Effects of Obinutuzumab on Cecal Ligation and Puncture Induced Septic Liver Injury in Rats
2028	ORAL PRESENTATION 42	25 April 2026, Saturday	07:30 - 09:00	Peng Qu	sepsis
2100	ORAL PRESENTATION 42	25 April 2026, Saturday	07:30 - 09:00	Maisam Akroush	From Organ to Surface: Perforating Disorders in Chronic Liver Disease
2152	ORAL PRESENTATION 42	25 April 2026, Saturday	07:30 - 09:00	Qiankun Hu	Circulating cell-free mitochondrial DNA predicts prognosis and triggers macrophage STING-dependent inflammation in acute-on-chronic liver failure




35TH ANNUAL MEETING OF THE ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER
 22-25 April 2026
 Istanbul Lütfi Kırdar International Convention and Exhibition Centre • İstanbul / Türkiye
www.apasl2026istanbul.org



Abstract No	Session Name	Session Date	Session Time	Presenter Name	Presentation Title
2195	ORAL PRESENTATION 42	25 April 2026, Saturday	07:30 - 09:00	Xueyun Zhang	3D Radiomics Analysis Based on Liver CT Imaging for Predicting Hepatic Encephalopathy in HBV-ACLF Patients
2218	ORAL PRESENTATION 42	25 April 2026, Saturday	07:30 - 09:00	Shan Zhong	Nucleos(t)ide Analogue Treatment History Stratifies Prognosis in Hepatitis B Virus-Related Acute-on-Chronic Liver Failure
2292	ORAL PRESENTATION 42	25 April 2026, Saturday	07:30 - 09:00	lufeng Li	Analysis of Clinical Characteristics and Treatment Outcomes in HBV - Related Liver Failure Patients with or without Diabetes Mellitus
2508	ORAL PRESENTATION 42	25 April 2026, Saturday	07:30 - 09:00	Anand Kulkarni	Midodrine with albumin improves ascites control in Acute-on-chronic liver failure: A Double Bind Randomized trial (MIDAS trial)
2527	ORAL PRESENTATION 42	25 April 2026, Saturday	07:30 - 09:00	Pelin Telli	Prognostic Stratification of Non-Ischemic Acute Liver Injury in the Emergency Department: A Retrospective Cohort Study
1085	ORAL PRESENTATION 43	25 April 2026, Saturday	07:30 - 09:00	Fatih İşik	Radiomics on Gadoteric Acid HBP MRI to Distinguish Subclinical Hepatic Parenchymal Disease from Normal Liver
1123	ORAL PRESENTATION 43	25 April 2026, Saturday	07:30 - 09:00	Shifan Liu	From Cirrhosis to Cancer: End-to-End Deep Learning Surveillance on Non-Contrast CT
1125	ORAL PRESENTATION 43	25 April 2026, Saturday	07:30 - 09:00	Hatice OGUR	Development of an Explainable Hybrid Artificial Intelligence System for Early Detection of Chronic Liver Diseases
2525	ORAL PRESENTATION 43	25 April 2026, Saturday	07:30 - 09:00	Federico Peralta	Adherence to an Admission Care Bundle and Its Impact on Outcomes in Decompensated Cirrhosis: A Multicenter Analytical Cross-Sectional Study
2602	ORAL PRESENTATION 43	25 April 2026, Saturday	07:30 - 09:00	GİZEM DAĞCI	Effect of Midodrine on Short Term Mortality and Liver Function in Patients with Cirrhosis and Ascites: A Systematic Review and Meta-analysis
2660	ORAL PRESENTATION 43	25 April 2026, Saturday	07:30 - 09:00	Md. Shakhawat Hossain	The Silent Summer Threat: Significant Seasonal Worsening of Electrolyte Imbalance in Cirrhosis Patients in a Tropical Climate Calls for Dynamic Diuretic Dosing
2672	ORAL PRESENTATION 43	25 April 2026, Saturday	07:30 - 09:00	JAYASHREE BISWAS	Predictors of Post-TIPS Persistent Ascites
2691	ORAL PRESENTATION 43	25 April 2026, Saturday	07:30 - 09:00	Sayan Malakar	Splenic Stiffness Measurement to PRÉdict Decompensation in Patients with Compensated Advanced Chronic Liver Disease in India (SPRED-c-ACLD study)
2736	ORAL PRESENTATION 43	25 April 2026, Saturday	07:30 - 09:00	Manu Rajeev	Thalidomide reduces transfusion requirements due to gastrointestinal vascular malformations in patients with liver cirrhosis
1072	ORAL PRESENTATION 44	25 April 2026, Saturday	07:30 - 09:00	Vahe Azatyan	Comparative evaluation of the level of oral microflora in patients with viral hepatitis C using heated tobacco product and cigarette smoking in Armenia: a pilot study
1144	ORAL PRESENTATION 44	25 April 2026, Saturday	07:30 - 09:00	Akshit Vats	The GREM1–BMP7 axis orchestrates apoptosis-driven fibrotic remodeling in biliary atresia
1378	ORAL PRESENTATION 44	25 April 2026, Saturday	07:30 - 09:00	Nupur Sharma	Leucine-rich alpha-2-glycoprotein 1 turnover imbalance impairs regenerative signaling in Alcohol-associated Hepatitis
1625	ORAL PRESENTATION 44	25 April 2026, Saturday	07:30 - 09:00	Yu Zhang	Alcohol Consumption Accelerates Liver Fibrosis in Chronic Hepatitis B: Evidence from Mendelian Randomization and a Prospective Cohort Study
1634	ORAL PRESENTATION 44	25 April 2026, Saturday	07:30 - 09:00	Yifan Xu	Integrated Plasma and Fecal Metabolic Profiling in Alcoholic Cirrhosis: Association with Gut Microbiota Dysbiosis
1735	ORAL PRESENTATION 44	25 April 2026, Saturday	07:30 - 09:00	Mohit Varshney	Policy Blind Spots and Clinical Realities: Determinants of Continued Alcohol Use in Alcohol-Associated Liver Disease at India's First Integrated AUD–ALD Clinic
1754	ORAL PRESENTATION 44	25 April 2026, Saturday	07:30 - 09:00	Qi Shen Shen	The mechanism of TMBIM5 in ameliorating alcohol-related liver disease by regulating mitochondrial dynamics
2541	ORAL PRESENTATION 44	25 April 2026, Saturday	07:30 - 09:00	Hasan Buran	Alcoholic Liver Transplants Performed Due to Liver Disease: A Single-Center Experience
2886	ORAL PRESENTATION 44	25 April 2026, Saturday	07:30 - 09:00	Pavithra Senadheera	Comparative Analysis of Epidemiological Research Output: Metabolic Dysfunction-Associated Steatotic Liver Disease vs. Alcohol-Associated Liver Disease
1025	ORAL PRESENTATION 45	25 April 2026, Saturday	07:30 - 09:00	Jun-Hao Mei	Real-time multidimensional system for predicting survival in patients with advanced biliary tract cancer treated with immuno-chemotherapy
1110	ORAL PRESENTATION 45	25 April 2026, Saturday	07:30 - 09:00	Mark Angelo Pado	Effectiveness and safety of Fibrate Therapy in the treatment of adults with Primary Sclerosing Cholangitis: A Systematic Review and Meta-Analysis
1257	ORAL PRESENTATION 45	25 April 2026, Saturday	07:30 - 09:00	Yu Huang	Si-Ni-San, a traditional Chinese herbal formula, ameliorates cholestatic liver injury by targeting the calcium-sensing receptor (CaSR)/MAPK pathway
1418	ORAL PRESENTATION 45	25 April 2026, Saturday	07:30 - 09:00	Li Wei	Efficacy of Sulfasalazine in Patients with Primary Biliary Cholangitis and Incomplete Response to Ursodeoxycholic Acid
1482	ORAL PRESENTATION 45	25 April 2026, Saturday	07:30 - 09:00	Jing Liang	From Gene Expression Profiles to Functional Networks: A Multi-Omics Integrative Analysis of Methyl Eugenol Promoting Cholangiocarcinoma Development
2368	ORAL PRESENTATION 45	25 April 2026, Saturday	07:30 - 09:00	Abhishak GUPTA	Dynamic Metabolic Reprogramming Drives Adipose Fibrosis in a High-Fat Diet-Induced Obesity in Mice Model
2406	ORAL PRESENTATION 45	25 April 2026, Saturday	07:30 - 09:00	Jing Chen	Benefit of treatment expansion: A Comparative Analysis of EASL 2025, AASLD 2025, and APASL 2026 Clinical Practice Guidelines for Management of Chronic Hepatitis B
2461	ORAL PRESENTATION 45	25 April 2026, Saturday	07:30 - 09:00	Mohamed Elsaid	Early GI/Hepatology Subspecialty Access in Cirrhosis and Survival: A Retrospective Cohort Analysis
2673	ORAL PRESENTATION 45	25 April 2026, Saturday	07:30 - 09:00	Yuyuan Jia	Parallel Comparison of Two HBV pg RNA Detection Assays
1619	ORAL PRESENTATION 46	25 April 2026, Saturday	07:30 - 09:00	Qing-Lei Zeng	Safety and Effectiveness of Peginterferon Alfa-2b Combined with Tenofovir Amibufenamide in Patients with Chronic Hepatitis B
1646	ORAL PRESENTATION 46	25 April 2026, Saturday	07:30 - 09:00	Yuxi Shi	Mapping the Global Network of Viral Hepatitis A, B, C and E: Unveiling Disease-Specific Epidemic Architectures through Complex Network Analysis
1647	ORAL PRESENTATION 46	25 April 2026, Saturday	07:30 - 09:00	Mingyang Feng	Antiviral Therapy in Patients with HBV Infection in the HBeAg-Negative Indeterminate Phase
1653	ORAL PRESENTATION 46	25 April 2026, Saturday	07:30 - 09:00	Menghan Jin	Efficacy of sofosbuvir/velpatasvir in patients with hepatitis C virus genotype 3 infection
1661	ORAL PRESENTATION 46	25 April 2026, Saturday	07:30 - 09:00	Zain Majid	Clinical Characteristics of Autoimmune Hepatitis in Patients with Hepatitis B–D Coinfection: A Case Series
1664	ORAL PRESENTATION 46	25 April 2026, Saturday	07:30 - 09:00	Hua-xiang Yang	Matrix Stiffness Suppresses Hepatitis B Virus Replication via YAP-Mediated Intrinsic Antiviral Signaling
1673	ORAL PRESENTATION 46	25 April 2026, Saturday	07:30 - 09:00	Pius Takyi	Towards hepatitis B elimination in Ghana: vaccination coverage and its predictors among informal sector workers in Kejetia, Kumasi, Ghana
1690	ORAL PRESENTATION 46	25 April 2026, Saturday	07:30 - 09:00	Petek Şarlak Konya	Off-Therapy Outcomes After Long-Term Nucleos(t)ide Analogue Treatment in HBeAg-Negative Chronic Hepatitis B
1694	ORAL PRESENTATION 46	25 April 2026, Saturday	07:30 - 09:00	Hamza Benazzouz	Non-Invasive Evaluation of Fibrosis Regression in HBV and HCV: A Real-World Comparative Analysis
1023	ORAL PRESENTATION 47	25 April 2026, Saturday	07:30 - 09:00	Ajay Patwa	Real-world Clinical and Procedural Insights into Liver Abscesses: A Multidimensional Retrospective Analysis from a Tertiary Center in North India
1820	ORAL PRESENTATION 47	25 April 2026, Saturday	07:30 - 09:00	Chihiro Miwa	Downstaging by Atezolizumab plus Bevacizumab in Advanced Hepatocellular Carcinoma: Identifying Candidates for Conversion Therapy Based on Tumor Biology and Vascular Invasion Patterns
1918	ORAL PRESENTATION 47	25 April 2026, Saturday	07:30 - 09:00	James Manuel Medalla	Solving a Recurrent Hepatic Abscesses Through Discovery of a Cholecystoduodenal Fistula resulting from an Over-the-Scope Clip closure of Duodenal Perforation as a complication of Microwave Ablation for HCC
2092	ORAL PRESENTATION 47	25 April 2026, Saturday	07:30 - 09:00	Yu Jun Wong	Paris-II Outperforms Other UDCA Response Criteria to predict Transplant-Free Survival in Asian PBC Patients
2102	ORAL PRESENTATION 47	25 April 2026, Saturday	07:30 - 09:00	Abhimati Ravikulan	Temporal Trends and Outcomes of AMA-Negative Primary Biliary Cholangitis in a Multi-Centre South-East Asian Cohort
2192	ORAL PRESENTATION 47	25 April 2026, Saturday	07:30 - 09:00	Xinghuan Fu	Neutrophil recruited CD38hi cytotoxic CD8 T cells characterize the T cell infiltrate in checkpoint inhibitor-mediated cholangitis
2225	ORAL PRESENTATION 47	25 April 2026, Saturday	07:30 - 09:00	Emerald T. Gersava	Infected Choledochal Cysts Masking as Liver Abscesses in an Adult Male: A Case Report
2440	ORAL PRESENTATION 47	25 April 2026, Saturday	07:30 - 09:00	Kedsiree Sanit	Clinical outcomes and treatment response in primary biliary cholangitis with and without autoimmune hepatitis features: a Thai multicenter 10-year cohort
2832	ORAL PRESENTATION 47	25 April 2026, Saturday	07:30 - 09:00	Rino Alvani Gani	Immune-Excluded CD4⁺ and CD8⁺ T-Cell Depletion Predicts Early Recurrence in Hepatocellular Carcinoma with Microvascular Invasion
1607	ORAL PRESENTATION 48	25 April 2026, Saturday	07:30 - 09:00	Zhewen Zhou	From Dysbiosis to Prediction: A Novel Gut Microbiota–Derived Index for Spontaneous Bacterial Peritonitis in HBV-Related Cirrhosis
1608	ORAL PRESENTATION 48	25 April 2026, Saturday	07:30 - 09:00	Lei Shi	Two-Year Follow-up of a Dose-Escalation Trial of Mesenchymal Stromal Cell Therapy for Decompensated Liver Cirrhosis
1624	ORAL PRESENTATION 48	25 April 2026, Saturday	07:30 - 09:00	Chenglin Sun	A Noninvasive Model Based on Liver and Spleen Microcirculatory Perfusion Parameters for Predicting High-Risk Varices in CHB-Related Cirrhosis
1662	ORAL PRESENTATION 48	25 April 2026, Saturday	07:30 - 09:00	Md. Sabbir Hossain	Socioeconomic Disparities and Potential Impact of Delayed Presentation on the Burden of Portal Hypertension in a Bangladeshi Tertiary Care Setting
1713	ORAL PRESENTATION 48	25 April 2026, Saturday	07:30 - 09:00	Han Ding	Hepatocyte myb-like swirm and mpn domains 1 exacerbates liver fibrosis by stabilizing gelsolin via k29-linked deubiquitination
1715	ORAL PRESENTATION 48	25 April 2026, Saturday	07:30 - 09:00	Eman Abdelsameea	THE OUTCOME PREDICTION ROLE OF RED CELL DISTRIBUTION WIDTH IN 1000 HOSPITALIZED CIRRHOTIC EGYPTIAN PATIENTS
1727	ORAL PRESENTATION 48	25 April 2026, Saturday	07:30 - 09:00	Riad Mohammad Moshaed Hossain	Diagnosis of the differentials of ascites in low-resource settings.
1769	ORAL PRESENTATION 48	25 April 2026, Saturday	07:30 - 09:00	UDIT VAISH	Admission NLR and APRI as Practical, Low-Cost Predictors of Severity in Cirrhosis: Data from an Indian Tertiary Center
1771	ORAL PRESENTATION 48	25 April 2026, Saturday	07:30 - 09:00	Hak Keith Leung	Our Journey Towards a Dedicated Transjugular Intrahepatic Portosystemic Shunt (TIPS) Service: Teamwork Makes the Dream Work
2463	ORAL PRESENTATION 49	25 April 2026, Saturday	07:30 - 09:00	Paul Miguel Perez	Association of Long-Term Glycemic Control with the Risk of Developing Cirrhosis in Type 2 Diabetes Mellitus: A 5-Year Multi-Center Retrospective Cohort Study of Liver Outcomes and Predictive Factors
2534	ORAL PRESENTATION 49	25 April 2026, Saturday	07:30 - 09:00	ALYSSA CHAN	ASSESSMENT OF ACCURACY OF PLATELET COUNT/SPLEEN DIAMETER RATIO IN PREDICTING THE PRESENCE OF ESOPHAGEAL VARICES IN FILIPINO PATIENTS WITH CIRRHOSIS AT SLMC-QC
2543	ORAL PRESENTATION 49	25 April 2026, Saturday	07:30 - 09:00	Sam Fandood	Prevalence and risk factors of esophageal and gastroesophageal varices in myeloproliferative neoplasm patients with portal hypertension in a tertiary government hospital: a 5-year cross-sectional study




35TH ANNUAL MEETING OF THE ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER
22-25 April 2026
Istanbul Lütfi Kırdar International Convention and Exhibition Centre • İstanbul / Türkiye
www.apasi2026istanbul.org



Abstract No	Session Name	Session Date	Session Time	Presenter Name	Presentation Title
2593	ORAL PRESENTATION 49	25 April 2026, Saturday	07:30 - 09:00	Cheng Zeng	Spermidine suppresses liver fibrosis by remodeling the communication signal between liver sinusoidal endothelial cells and hepatic stellate cells Running title: Spermidine suppresses liver fibrosis by downregulation of LSEC-derived BGN
2594	ORAL PRESENTATION 49	25 April 2026, Saturday	07:30 - 09:00	Runling Zhang	Risk factors for low-level viremia in Tenofovir Disoproxil Fumarate (TDF)-treated patients with chronic hepatitis B complicated by advanced hepatic fibrosis/compensated liver cirrhosis
2605	ORAL PRESENTATION 49	25 April 2026, Saturday	07:30 - 09:00	Yang Liu	Mobile Ablation for Secondary Hypersplenism in Hepatocellular Carcinoma Patients with Liver Cirrhosis: A Safety and Efficacy Study
2607	ORAL PRESENTATION 49	25 April 2026, Saturday	07:30 - 09:00	Jingyu Zhang	Inhibition of FKBP10 attenuates hepatic stellate cell activation and liver fibrosis via RAS signaling
2612	ORAL PRESENTATION 49	25 April 2026, Saturday	07:30 - 09:00	SAUL SUAYBAGUIO	Accuracy of D-dimer Levels in Predicting Clinical Outcomes of Patients with Decompensated Liver Cirrhosis in a Philippine Tertiary Hospital
2625	ORAL PRESENTATION 49	25 April 2026, Saturday	07:30 - 09:00	Jeremie Manarang	Procedural-Related Bleeding Among Patients with Liver Cirrhosis in a Tertiary Hospital in the Philippines: A Five-Year Review
1725	ORAL PRESENTATION 50	25 April 2026, Saturday	09:00 - 10:30	Ruifeng Yang	Suboptimal sensitivity of quantitative HBcrAg assay for managing HBeAg-negative chronic hepatitis B
1738	ORAL PRESENTATION 50	25 April 2026, Saturday	09:00 - 10:30	Yuying Chen	Combination Therapy with Toll-like receptor 7 Agonist and Programmed Death Ligand 1 Antibody Restores HBV-Specific CD8+ T Cells in Virally suppressed Chronic Hepatitis B
1747	ORAL PRESENTATION 50	25 April 2026, Saturday	09:00 - 10:30	Jian Wu	Predictive Biomarkers for Hepatitis E Virus-Related Acute Liver Failure Based on Lipidomics and Transcriptomics
1753	ORAL PRESENTATION 50	25 April 2026, Saturday	09:00 - 10:30	Jason Phowira	Allogeneic Umbilical Cord Mesenchymal Stem Cell Transplantation in Patients with Cirrhosis Caused by Hepatitis B: A Single-Center Case Series
1776	ORAL PRESENTATION 50	25 April 2026, Saturday	09:00 - 10:30	Sujun Zheng	Immune characteristics of peripheral blood cells in inactive hepatitis B surface antigen carriers treated with interferon
1782	ORAL PRESENTATION 50	25 April 2026, Saturday	09:00 - 10:30	Sharker Mohammad Shahadat Hossain	An Evaluation of the Effectiveness of Entecavir in Patients with Acute Chronic Hepatitis B liver Failure
1802	ORAL PRESENTATION 50	25 April 2026, Saturday	09:00 - 10:30	Man Li	Hesperidin inhibits HBV via promoting macrophage M1 polarization through activation of the NF- κ B/CXCL/TNF α pathway
1819	ORAL PRESENTATION 50	25 April 2026, Saturday	09:00 - 10:30	Ahmet Sertçelik	Impact of the expanded program on immunization on Hepatitis B elimination efforts: Insights from a Turkish reference center
1822	ORAL PRESENTATION 50	25 April 2026, Saturday	09:00 - 10:30	Xin Wang	Blood biomarkers for non-invasive diagnosis of advanced fibrosis or compensated cirrhosis in chronic hepatitis B
2635	ORAL PRESENTATION 51	25 April 2026, Saturday	09:00 - 10:30	Yuzhu Song	Endothelial RGS16 Attenuates Hepatic Fibrosis by Restricting Pathological
2654	ORAL PRESENTATION 51	25 April 2026, Saturday	09:00 - 10:30	Qiang Li	Comparison of the diagnostic accuracy of magnetic resonance elastography, FibroScan, and serum fibrosis models for detecting liver fibrosis and cirrhosis in chronic liver diseases: a multicohort study across all aetiologies
2670	ORAL PRESENTATION 51	25 April 2026, Saturday	09:00 - 10:30	Changqing Guo	Endoscopic Ultrasound-Guided Partial Splenic Embolization in Hypersplenism: A Novel Approach Validated in a pilot study
2706	ORAL PRESENTATION 51	25 April 2026, Saturday	09:00 - 10:30	Haiyu Wang	A Novel Non-invasive Model to Identify High Risk Varices in Patients with HBV-related Cirrhosis
2731	ORAL PRESENTATION 51	25 April 2026, Saturday	09:00 - 10:30	Chihao Zhang	Tbx1 alleviated hepatic encephalopathy by promoting meningeal lymphangiogenesis and drainage of senescent astrocytes via a CCL21-dependent manner
2781	ORAL PRESENTATION 51	25 April 2026, Saturday	09:00 - 10:30	EINA MARIE LI	Dual noninvasive prediction of esophageal varices in cirrhosis using transient elastography and echocardiographic parameters: an interim machine learning analysis
2799	ORAL PRESENTATION 51	25 April 2026, Saturday	09:00 - 10:30	Zhandong Lin	Cathepsin K Attenuates Liver Fibrosis by Suppressing TGF- β /Smad Signaling via T β RII Degradation
2810	ORAL PRESENTATION 51	25 April 2026, Saturday	09:00 - 10:30	Sajid Jalil	Sodium Glucose Co-Transporter 2 Inhibitors Use in Diabetic Patients with Cirrhosis Improves Liver-related Outcomes and Survival
2276	ORAL PRESENTATION 52	25 April 2026, Saturday	10:50 - 12:10	Jian Wang	Long-Term Outcomes of Treatment-Induced Versus Spontaneously Achieved HBsAg <100 IU/mL in Chronic Hepatitis B
2282	ORAL PRESENTATION 52	25 April 2026, Saturday	10:50 - 12:10	Leer Shen	SIRT2 restrains HDV-associated hepatic macrophage pyroptosis by deacetylating NLRP3 and suppressing NF- κ B signaling
2294	ORAL PRESENTATION 52	25 April 2026, Saturday	10:50 - 12:10	Elif Gucyetmez	Comparison of the Effects of Tenofovir Alafenamide and Entecavir on Lipid Profiles in Anti-HBc Positive Kidney Transplant Recipients
2306	ORAL PRESENTATION 52	25 April 2026, Saturday	10:50 - 12:10	Yanwei Zhong	Study on Key Inflammatory Proteins of Antiviral Treatment in Children with Chronic Hepatitis B
2377	ORAL PRESENTATION 52	25 April 2026, Saturday	10:50 - 12:10	Yaqin Zhang	Efficacy Differences of Interferon Combined with Nucleos(t)ide Analogs in Treating HBeAg-Positive Chronic Hepatitis B Stratified by Baseline Liver Fibrosis Indicators
2389	ORAL PRESENTATION 52	25 April 2026, Saturday	10:50 - 12:10	Qiran Zhang	Towards Individualized Interferon Therapy in Hepatitis B: HBsAg Kinetics and Seroclearance upon Baseline HBsAg Levels and Treatment Duration
2404	ORAL PRESENTATION 52	25 April 2026, Saturday	10:50 - 12:10	Chao Jiang	Development and validation of a dynamic nomogram for predicting significant liver injury in chronic hepatitis B patients with indeterminate phase
2410	ORAL PRESENTATION 52	25 April 2026, Saturday	10:50 - 12:10	Ruirui You	Hepatitis B Virus Core Antibody Seroconversion and Risk of Hepatitis B Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation
2457	ORAL PRESENTATION 52	25 April 2026, Saturday	10:50 - 12:10	Yelda Öğütmen	Impact of the national Hepatitis B vaccination program on HBsAg seroprevalence in pregnant women and comparison with migrant pregnant women
1580	ORAL PRESENTATION 53	25 April 2026, Saturday	10:50 - 12:10	ALİ ÇAĞRI ORAL	Prognostic Evaluation of Hepatocellular Carcinoma: Impact of Etiological Factors on Survival Outcomes
1581	ORAL PRESENTATION 53	25 April 2026, Saturday	10:50 - 12:10	Hongli Yu Yu	Continuing or Switching Systemic Therapy Combined with Locoregional Therapy Defines a Personalized Strategy for Oligoprogression in HCC: A Multicenter Retrospective Study
1592	ORAL PRESENTATION 53	25 April 2026, Saturday	10:50 - 12:10	Abdel Ghani Atef Abdel Ghani Badran	Fibroscan role in determining the patients who are at high risk for developing HCC in 1000 cirrhotic Egyptian patients.
1596	ORAL PRESENTATION 53	25 April 2026, Saturday	10:50 - 12:10	Minjun liao	ABT score based clinical model predicts prognosis in unresectable hepatocellular carcinoma treated with TACE combined with Bevacizumab and Sintilimab therapy
1603	ORAL PRESENTATION 53	25 April 2026, Saturday	10:50 - 12:10	Qianting Guan	Fc γ R2b mediates CD8+ T cells dysfunction in Hepatocellular Carcinoma
1640	ORAL PRESENTATION 53	25 April 2026, Saturday	10:50 - 12:10	Xiangchang Zeng	The α -hydroxybutyrylation modification of ACSL4 inhibits the growth of hepatocellular carcinoma
1676	ORAL PRESENTATION 53	25 April 2026, Saturday	10:50 - 12:10	Hayriye Dilan Çağlar	Predictive Factors of Tyrosine Kinase Inhibitor Response in Patients with Advanced Hepatocellular Carcinoma
1757	ORAL PRESENTATION 53	25 April 2026, Saturday	10:50 - 12:10	Yeo Wool Kang	Impact of etiology on outcomes with atezolizumab plus bevacizumab in advanced hepatocellular carcinoma: A multicenter propensity-matched analysis
1758	ORAL PRESENTATION 53	25 April 2026, Saturday	10:50 - 12:10	Yue Huang	Predictive Role of Spleen Stiffness in Gastrointestinal Bleeding for Patients with Unresectable Hepatocellular Carcinoma Undergoing Systemic Therapy
1949	ORAL PRESENTATION 54	25 April 2026, Saturday	10:50 - 12:10	Mohammad Shariq	Development and Evaluation of Polyherbal Chitosan Nanoparticles: Antioxidant and Cytotoxic Effects on HepG2 Cells
1985	ORAL PRESENTATION 54	25 April 2026, Saturday	10:50 - 12:10	Ayşegül Öztürk	Effects of Linalool-Regorafenib Combination on Anticancer Activity in HUH-7 Cells
2000	ORAL PRESENTATION 54	25 April 2026, Saturday	10:50 - 12:10	Wanxin Shi	Efficacy of Yangyin Fuzheng Jiedu Prescription for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: An Evaluation Using Five Propensity Score Methods
2067	ORAL PRESENTATION 54	25 April 2026, Saturday	10:50 - 12:10	Jinpeng Li	Hepatic Arterial Infusion Chemotherapy Combined with Donafenib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma with Lung Metastases: A Multicenter Retrospective Study
2081	ORAL PRESENTATION 54	25 April 2026, Saturday	10:50 - 12:10	Mohammad Forhad Abedin Abedin	Late Presentation and Poor Outcomes of Hepatocellular Carcinoma in a Resource-Limited Setting: An Observational Study in a Tertiary Care Hospital, Bangladesh
2083	ORAL PRESENTATION 54	25 April 2026, Saturday	10:50 - 12:10	Cun Wang	Targeting STK40 unleashes anti-tumor immunity by triggering tumor vulnerability and T cell reinvigoration
2094	ORAL PRESENTATION 54	25 April 2026, Saturday	10:50 - 12:10	Xuhui Ma	Inhibition of Aurora B Induces Senescence and Potentiates Immunotherapy in Hepatocellular Carcinoma
2113	ORAL PRESENTATION 54	25 April 2026, Saturday	10:50 - 12:10	Chen Yang	Unveiling occult squamous commitment as a clinical fate determinant in cholangiocarcinoma
2124	ORAL PRESENTATION 54	25 April 2026, Saturday	10:50 - 12:10	Abdul Samad Bhatti	GENDER DISPARITIES IN HEPATOCELLULAR CARCINOMA: A COMPARATIVE ANALYSIS
1069	ORAL PRESENTATION 55	25 April 2026, Saturday	10:50 - 12:10	Baoju Wang	Gut Microbiota-Derived Butyrate Alleviates the Progression of Metabolic Dysfunction-Associated Steatohepatitis by Regulating Intrahepatic CD4 ⁺ T Cell Immune Response
1071	ORAL PRESENTATION 55	25 April 2026, Saturday	10:50 - 12:10	Jishnu Jayarajan	Prevalence of significant fibrosis and metabolic correlates in patients with Metabolic dysfunction Associated Fatty Liver Disease: A cross-sectional study from a tertiary centre
1073	ORAL PRESENTATION 55	25 April 2026, Saturday	10:50 - 12:10	Soe Thiha Maung	Cognitive Impairment in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): A Systematic Review and Meta-analysis
1075	ORAL PRESENTATION 55	25 April 2026, Saturday	10:50 - 12:10	CLAUDINE FELICIANO	Effectiveness of Semaglutide in Non-Alcoholic Steatohepatitis resolution A meta-analysis and systematic review
1080	ORAL PRESENTATION 55	25 April 2026, Saturday	10:50 - 12:10	Sayfullo Avezov	Comparative Features of Viral and Metabolically Associated Liver Cirrhosis
1102	ORAL PRESENTATION 55	25 April 2026, Saturday	10:50 - 12:10	Jing Zhang	Natural History and Risk Factors of Metabolic Dysfunction-Associated Fatty Liver Disease in Chinese Cohorts: A Scoping Review
1139	ORAL PRESENTATION 55	25 April 2026, Saturday	10:50 - 12:10	Shamsul Mohd Zain	Sequential Application of the Fibrosis-4 Index and Serum Gamma-Glutamyl Transferase for Enhanced Detection of Advanced Fibrosis in Type 2 Diabetes Mellitus Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease
1170	ORAL PRESENTATION 55	25 April 2026, Saturday	10:50 - 12:10	Angel Cho Kan Ma	Nurse-led lifestyle modification intervention to improve self-efficacy, illness perception, self-management behaviours and liver steatosis among adults with metabolic dysfunction associated steatotic liver disease: A pilot randomised controlled trial
1172	ORAL PRESENTATION 55	25 April 2026, Saturday	10:50 - 12:10	Linying Lai	EMMPRIN Loss Promotes Fatty Acid Transport Protein FATP2 Lactylation in MAFLD via the MCTs-lactate Axis
1973	ORAL PRESENTATION 56	25 April 2026, Saturday	10:50 - 12:10	Haiying Zhang	Prognostic Utility of baseline and SVR12/24 M2BPGI for Liver-Related Events in hepatitis C patients
1989	ORAL PRESENTATION 56	25 April 2026, Saturday	10:50 - 12:10	TALAL BHATTI	Post-Polypectomy Bleeding in Patients with Cirrhosis: A Systematic Review of Risk, Predictors, and Procedure-Related Factors
2006	ORAL PRESENTATION 56	25 April 2026, Saturday	10:50 - 12:10	Faruk Karakeçili	Phenotypic Pattern of Acute Liver Injury in Crimean-Congo Hemorrhagic Fever Among Patients with Chronic Hepatitis B in an HBV-Endemic Region




35TH ANNUAL MEETING OF THE ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER
22-25 April 2026
Istanbul Lütfi Kırdar International Convention and Exhibition Centre • İstanbul / Türkiye
www.apasi2026istanbul.org



Abstract No	Session Name	Session Date	Session Time	Presenter Name	Presentation Title
2168	ORAL PRESENTATION 56	25 April 2026, Saturday	10:50 - 12:10	Ghulam Mohiuddin	Colorectal Carcinoma in Young patients, single Centre study from Karachi, Pakistan.
2241	ORAL PRESENTATION 56	25 April 2026, Saturday	10:50 - 12:10	Serap Türk	Diagnostic Value of Liver Biopsy in Unexplained Liver Enzyme Elevations: A Tertiary Center Experience
2274	ORAL PRESENTATION 56	25 April 2026, Saturday	10:50 - 12:10	春润 李	Blood-Stasis Constitution Drives Hepatic MDSC Accumulation in MASLD
2326	ORAL PRESENTATION 56	25 April 2026, Saturday	10:50 - 12:10	Teerha Piratvisuth	Asia-Pacific expert consensus on GAAD for hepatocellular carcinoma surveillance
2398	ORAL PRESENTATION 56	25 April 2026, Saturday	10:50 - 12:10	Mark Siñagan	Etiology-Specific Patterns of Liver Stiffness and Steatosis Assessed by Transient Elastography in a Tertiary Referral Center in Southern Philippines
2450	ORAL PRESENTATION 56	25 April 2026, Saturday	10:50 - 12:10	Yaren DIRIK	A rare case: Sporadic Burkitt lymphoma presenting with high serum-ascite albumin gradient and low ascite glucose
1185	ORAL PRESENTATION 57	25 April 2026, Saturday	10:50 - 12:10	Vipul Gautam	Perioperative Management, Ethical Concerns, and Outcomes of Pediatric Domino Liver Transplants from Maple Syrup Urine Disease Donors
2390	ORAL PRESENTATION 57	25 April 2026, Saturday	10:50 - 12:10	Zhen Tian	Ultrasonographic evaluation of gallbladder motor function in the diagnosis and prognosis of intrahepatic cholestasis of pregnancy
2394	ORAL PRESENTATION 57	25 April 2026, Saturday	10:50 - 12:10	Deepa Janakiraman	Demystifying primary hepatic Langerhans Cell Histiocytosis (LCH)- From pattern recognition to molecular diagnosis
2499	ORAL PRESENTATION 57	25 April 2026, Saturday	10:50 - 12:10	Sindhuja Thatti Audikesavalu	Wilson disease mutation pattern with genotype-phenotype correlations in paediatric cohort in south India
2511	ORAL PRESENTATION 57	25 April 2026, Saturday	10:50 - 12:10	Kalpana Panda	Diagnostic accuracy of blood-based non-invasive tests for screening of varices in children with portal-hypertension: A systematic review and meta-analysis
2693	ORAL PRESENTATION 57	25 April 2026, Saturday	10:50 - 12:10	Jyoti Bhutani	Muscle Matters: Impact of Sarcopenia on Mortality and Clinical Outcomes in Pediatric Liver Transplantation
1196	ORAL PRESENTATION 57	25 April 2026, Saturday	10:50 - 12:10	Aizirek Abdikaiyrova	Prevalence and severity of chronic atrophic gastritis in cirrhotic patients versus dyspeptic controls
2506	ORAL PRESENTATION 58	25 April 2026, Saturday	13:40 - 15:10	Selma Tosun	Evaluation of anti-HCV positivity, HCV RNA testing, and treatment status among individuals presenting to the hospital
2507	ORAL PRESENTATION 58	25 April 2026, Saturday	13:40 - 15:10	Jeong-Ju Yoo	High Treatment Adherence Reduces HCC in Cirrhosis, with Additional Benefit from TAF Running title : Adherence Lowers HCC Risk in Cirrhosis
2510	ORAL PRESENTATION 58	25 April 2026, Saturday	13:40 - 15:10	Bei Jiang	Efficacy of PegIFNα Add-on Therapy in Treatment-Experienced CHB Patients with Low-Level Viremia: A Large Prospective Cohort Study
2514	ORAL PRESENTATION 58	25 April 2026, Saturday	13:40 - 15:10	Furkan Kirsoy	Long-term Clinical Outcomes of Delta Hepatitis in A Single Center Experience
2531	ORAL PRESENTATION 58	25 April 2026, Saturday	13:40 - 15:10	Velat AYTEKİN	Evaluation of Leptospirosis Cases in the Şanlıurfa Region
2533	ORAL PRESENTATION 58	25 April 2026, Saturday	13:40 - 15:10	Jidong Jia	Cross-study analysis of HBsAg rebound following treatments of elebsiran/BRIL-179 in combination with peginterferon alfa
2560	ORAL PRESENTATION 58	25 April 2026, Saturday	13:40 - 15:10	Raad Rahmat	Predictive potential of hypermethylation of RASSF1A and CCND2 promoters in hepatitis B virus-induced hepatocellular carcinoma
2564	ORAL PRESENTATION 58	25 April 2026, Saturday	13:40 - 15:10	Yuyu Zeng	The relationship between the systemic immune-inflammation index and hepatitis C virus infection: NHANES 2005 to 2012
2576	ORAL PRESENTATION 58	25 April 2026, Saturday	13:40 - 15:10	Takako Inoue	Point-of-care HBcAg testing to identify high viral replication in chronic hepatitis B: a tool for supporting the WHO simplified treatment strategy in resource-limited settings
1813	ORAL PRESENTATION 59	25 April 2026, Saturday	13:40 - 15:10	Johanna Lynne La Rosa-Rimorin	Unmasking the unknown: the unexpected discovery of hepatic epithelioid hemangioendothelioma
1837	ORAL PRESENTATION 59	25 April 2026, Saturday	13:40 - 15:10	Yan Zhou	Early Ablation for Sub-centimeter Hepatocellular Carcinoma: Divergent Outcomes in Primary vs Recurrent Tumors over 10 Years
1848	ORAL PRESENTATION 59	25 April 2026, Saturday	13:40 - 15:10	Daniele Alek Calda	Metastatic Liver Involvement from Primary Adamantinoma-like Ewing Sarcoma of the Lung in an Elderly Male: A Rare Case Presentation
1849	ORAL PRESENTATION 59	25 April 2026, Saturday	13:40 - 15:10	Huiwen Yan	Yangyin Fuzheng Jiedu Prescription Reduces Recurrence Risk in Patients with Small Hepatocellular Carcinoma after Minimally Invasive Treatment: a Pragmatic Randomized Controlled Trial
1851	ORAL PRESENTATION 59	25 April 2026, Saturday	13:40 - 15:10	Liang Zhang Zhang	Inhibiting PPM1D facilitates the phosphorylation and oligomerization of VDAC2 to elicit immunogenic tumor destruction by activating cGAS-STING-IFN response
1867	ORAL PRESENTATION 59	25 April 2026, Saturday	13:40 - 15:10	Tianyi Xia	Identification of benefit subgroups from heterogeneous effects of adjuvant transarterial chemoembolization in hepatocellular carcinoma using causal model
1890	ORAL PRESENTATION 59	25 April 2026, Saturday	13:40 - 15:10	Yaoyao Yu	Deep Learning CT Signature for Predicting Occult Liver Metastases and Neoadjuvant Therapy Benefit in Pancreatic Ductal Adenocarcinoma: A Multicenter Retrospective Study
1899	ORAL PRESENTATION 59	25 April 2026, Saturday	13:40 - 15:10	Ying Lei	Exploring the value of imaging indicators in predicting TACE resistance in hepatocellular carcinoma based on contrast-enhanced CT
1906	ORAL PRESENTATION 59	25 April 2026, Saturday	13:40 - 15:10	Yuchan Xue	A Fe-Curcumin-based Strategy to Reinvigorate CAR-T Cells by Reversing Exhaustion and Senescence in Liver Cancer
2019	ORAL PRESENTATION 60	25 April 2026, Saturday	13:40 - 15:10	Nurgul Toktogulova	Cardiometabolic Risks in Elderly Individuals With Fatty Liver Living in Mid-Mountain Regions of Central Asia
2023	ORAL PRESENTATION 60	25 April 2026, Saturday	13:40 - 15:10	Zhuoru Jiang	Impact of Liver Fat Contents on Brain Structure and Cognitive Functions in Patients with MASLD
2039	ORAL PRESENTATION 60	25 April 2026, Saturday	13:40 - 15:10	Clothilde Philouze	Modelling liver fibrosis and MASH with humanized immune system mice
2065	ORAL PRESENTATION 60	25 April 2026, Saturday	13:40 - 15:10	Yan Wang	Comprehensive multiomics study of ballooned hepatocytes in MASH: Insights into cellular adaptation to metabolic overload
2066	ORAL PRESENTATION 60	25 April 2026, Saturday	13:40 - 15:10	SHUN LI	Phenotypic Age is a Hepatocentric Marker of Biological Aging: Stronger Associations of Liver-Related and Metabolic Outcomes over Cardiovascular Events in Steatotic Liver Disease
2087	ORAL PRESENTATION 60	25 April 2026, Saturday	13:40 - 15:10	Yixue Shu	CD146 Regulates Hepatocyte Lipotoxicity through Modulation of Mitochondrial Energy Metabolism and Inflammatory Response
2110	ORAL PRESENTATION 60	25 April 2026, Saturday	13:40 - 15:10	Abdul Samad	THE RISING THREAT OF MASLD IN YOUNG ADULTS: A COMPREHENSIVE METABOLIC AND HEPATIC ASSESSMENT FROM SOUTH ASIA
2245	ORAL PRESENTATION 60	25 April 2026, Saturday	13:40 - 15:10	Kiavash Semnani	Unravelling the placebo response in pharmacological trials for metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis
2255	ORAL PRESENTATION 60	25 April 2026, Saturday	13:40 - 15:10	Muhammad Siddique Chohan	Role of Metabolic Risk Factors in the Early Detection of Metabolic-Associated Steatotic Liver Disease (MASLD) in Young Adults: A Cross-Sectional Study
1022	ORAL PRESENTATION 61	25 April 2026, Saturday	15:30 - 17:00	Hao Wang	SLC1A5-dependent glutamine transport regulates macrophage senescence and efferocytosis during liver regeneration
1050	ORAL PRESENTATION 61	25 April 2026, Saturday	15:30 - 17:00	Ruifang Wang	Multicenter Study of Ultrasound-Guided Microwave Ablation for Hepatic Cystic Echinococcosis
2834	ORAL PRESENTATION 61	25 April 2026, Saturday	15:30 - 17:00	Ma. Angelica Goldamier Cannu	Epidemiologic and Clinical Trends in Hepatocellular Carcinoma: A Glimpse Through the Lens of Systemic Therapy Availability
2839	ORAL PRESENTATION 61	25 April 2026, Saturday	15:30 - 17:00	Jann Christian Solis	CAN EARLY CHANGES IN ALPHA-FETOPROTEIN PREDICT RADIOLOGIC RESPONSE AND OVERALL SURVIVAL IN IMMUNE CHECKPOINT INHIBITOR-BASED THERAPY OF HEPATOCELLULAR CARCINOMA?
2844	ORAL PRESENTATION 61	25 April 2026, Saturday	15:30 - 17:00	Yiming Wang	AARS1 promotes tumor progression and immune evasion via ATF6 lactylation-mediated tryptophan metabolism in hepatocellular carcinoma
2859	ORAL PRESENTATION 61	25 April 2026, Saturday	15:30 - 17:00	Dr.ANAND V KULKARNI	Profile of Hepatocellular Carcinoma in India: A Five-Year Prospective Study
2874	ORAL PRESENTATION 61	25 April 2026, Saturday	15:30 - 17:00	Jie Han	Dynamic evolution of the gut microbiome predicts therapeutic response in liver cancer: A large-scale longitudinal study with a cross-cohort meta-analysis
2876	ORAL PRESENTATION 61	25 April 2026, Saturday	15:30 - 17:00	DEEPAK JHA	Immune Checkpoint Inhibitor-Induced Hepatitis in HCC: Poor Response to Immunosuppression.
2877	ORAL PRESENTATION 61	25 April 2026, Saturday	15:30 - 17:00	Hikmet Akkiz	The Effect of Portal Vein Tumor Thrombosis on Survival in Patients with Hepatocellular Carcinoma Treated with Different Therapies
2647	ORAL PRESENTATION 62	25 April 2026, Saturday	15:30 - 17:00	Yang Yang	Quercetin ameliorates MASLD progression through the inhibition of the hexosamine biosynthesis pathway-mediated TAB2 protein O-GlcNAcylation
2664	ORAL PRESENTATION 62	25 April 2026, Saturday	15:30 - 17:00	Jiyuan Zhou	Integrating genetic omics and functional omics to identify clinically actionable gut microbiota-host interface targets in MASLD
2671	ORAL PRESENTATION 62	25 April 2026, Saturday	15:30 - 17:00	hang chen	Mechanistic Study of Resmetromir in Treating MAFLD Mouse Model: Gut Microbiota Remodeling and Metabolic Regulation
2714	ORAL PRESENTATION 62	25 April 2026, Saturday	15:30 - 17:00	Guanjing Lang	Exposure to Legacy and Replacement PFAS Is Associated with Metabolic Dysfunction-Associated Steatotic Liver Disease in Women
2759	ORAL PRESENTATION 62	25 April 2026, Saturday	15:30 - 17:00	da wang	αKB downregulates miRNA-363-3p and targets SERCA2b to alleviate hepatic endoplasmic reticulum stress and steatosis in MAFLD
2762	ORAL PRESENTATION 62	25 April 2026, Saturday	15:30 - 17:00	Danielle Lucero	The Effects of Nomenclature Change on the Epidemiology of Fatty/Steatotic Liver Disease
2765	ORAL PRESENTATION 62	25 April 2026, Saturday	15:30 - 17:00	Muh syaiful akbar	Disability Adapted Digital Therapeutics as a Precision Strategy for MASLD Risk Modulation: Longitudinal Neuromuscular in Lower Limb Amputees
2773	ORAL PRESENTATION 62	25 April 2026, Saturday	15:30 - 17:00	QIQIANQIAN ZHENG	Mechanistic Role of MFN2-FSP27 Mediated Lipid Droplet-Mitochondria Interactions in Metabolic Dysfunction-associated Steatohepatitis
2779	ORAL PRESENTATION 62	25 April 2026, Saturday	15:30 - 17:00	Ammar ALRAMADAN	Re-evaluation of Liver Biopsy Specimens Performed for Presumed Chronic Hepatitis B and Investigation of the Prevalence of MASLD
1642	ORAL PRESENTATION 63	25 April 2026, Saturday	15:30 - 17:00	Wen Zhao	Heme oxygenase-1 inhibiting mitochondrial apoptosis in metabolic associated fatty liver disease
1717	ORAL PRESENTATION 63	25 April 2026, Saturday	15:30 - 17:00	Miaomiao Tian	A new switch for lactate accumulation in metabolic dysfunction-associated steatotic liver disease
1729	ORAL PRESENTATION 63	25 April 2026, Saturday	15:30 - 17:00	Zilong Wang	The expression of Fmn1 in monocyte-derived macrophages promotes hepatic inflammation in MAFLD
1732	ORAL PRESENTATION 63	25 April 2026, Saturday	15:30 - 17:00	Jian Zhao	Associations of sweetened beverages consumption with the risk of MASLD and its related outcomes across genetic risk profiles: a prospective population-based cohort study




**35TH ANNUAL MEETING OF THE ASIAN PACIFIC
ASSOCIATION FOR THE STUDY OF THE LIVER**
22-25 April 2026
Istanbul Lütfi Kırdar International Convention and Exhibition Centre • İstanbul / Türkiye
www.apasl2026istanbul.org



Abstract No	Session Name	Session Date	Session Time	Presenter Name	Presentation Title
1815	ORAL PRESENTATION 63	25 April 2026, Saturday	15:30 - 17:00	Qianli Zhao	Efficacy of Silybin Phospholipid Complex in Metabolic-Associated Fatty Liver Disease
1821	ORAL PRESENTATION 63	25 April 2026, Saturday	15:30 - 17:00	Tianyuan Yang	Adolescent MASLD Incidence Trends, 1990–2023: Global and National Perspectives
1908	ORAL PRESENTATION 63	25 April 2026, Saturday	15:30 - 17:00	Adinda Amalia	Performance of Baveno VII Criteria in Predicting Clinically Significant Portal Hypertension in Burned-Out MAFLD
1935	ORAL PRESENTATION 63	25 April 2026, Saturday	15:30 - 17:00	Yinuo Yang	Neuropilin-1 alleviates metabolic dysfunction-associated fatty liver disease by promoting lysosomal degradation of toll-like receptor 4 in macrophages
1945	ORAL PRESENTATION 63	25 April 2026, Saturday	15:30 - 17:00	Betül Tunç Demirci	Impact of Microbiome in Obese vs Lean Steatotic Liver Disease in Children
1356	ORAL PRESENTATION 64	25 April 2026, Saturday	17:10 - 18:30	Pengxuan Wu	Severe Hepatic Steatosis Impairs PEG-IFN Response in HBsAg Clearance-Favorable Chronic Hepatitis B: A Retrospective Cohort Study
1652	ORAL PRESENTATION 64	25 April 2026, Saturday	17:10 - 18:30	minshan huang	Investigating the Role of Gut Microbiota-Derived Valine in Treating MAFLD through PPAR Signaling
1965	ORAL PRESENTATION 64	25 April 2026, Saturday	17:10 - 18:30	Maurice Michel	Modeling the burden of steatotic liver disease and its subcategories in people living with HIV
2172	ORAL PRESENTATION 64	25 April 2026, Saturday	17:10 - 18:30	Alaa M. Mostafa	The coexistence of MAFLD exacerbates liver fibrosis in patients with chronic hepatitis B.
2336	ORAL PRESENTATION 64	25 April 2026, Saturday	17:10 - 18:30	Farhana Kayani	Lean MAFLD in Chronic Hepatitis B: Clinical Characteristics, Fibrosis Risk and antiviral response in a Pakistani Cohort
2340	ORAL PRESENTATION 64	25 April 2026, Saturday	17:10 - 18:30	Jalal Khan	Metabolic Fatty Liver Masks Hepatitis B Activity: Implications for ALT-Based Treatment Decisions, a study from PAKistan
2897	ORAL PRESENTATION 64	25 April 2026, Saturday	17:10 - 18:30	Yichen Peng	Integrative Metabolomic and Cytokine Profiling Reveals a "Metabolic-Inflammatory" Signature in Chronic Hepatitis B Combined with Metabolic Dysfunction-Associated Fatty Liver Disease
1459	ORAL PRESENTATION 64	25 April 2026, Saturday	17:10 - 18:30	Meti Metiani	Revisiting HepaScore: New Evidence for Non-Invasive Fibrosis Assessment in Indonesian Patients with Chronic Hepatitis B
1461	ORAL PRESENTATION 65	25 April 2026, Saturday	17:10 - 18:30	Chuyue Xiong	A Retrospective Study on PD-1/CTLA-4 Bispecific Antibody Therapy Promoting Partial Functional Cure of Hepatitis B in Patients with HBV-Related Hepatocellular Carcinoma
1466	ORAL PRESENTATION 65	25 April 2026, Saturday	17:10 - 18:30	Yijing Cai	A new prediction model based on plasma ammonia and the Chinese Group on the Study of Severe Hepatitis B-ACLF-8545; score for patients with Hepatitis B virus-related acute-on-chronic liver failure.
1472	ORAL PRESENTATION 65	25 April 2026, Saturday	17:10 - 18:30	Xiaoman Liu	Divergent immune resolution and protracted immuno-metabolic memory in hepatitis E revealed by cross-species multi-omics
1517	ORAL PRESENTATION 65	25 April 2026, Saturday	17:10 - 18:30	Fatma Merve Kocak	Hepatitis B serology and vaccine response in uveitis patients treated with adalimumab: effects of the 1998 national hepatitis B vaccination program in Turkey
1525	ORAL PRESENTATION 65	25 April 2026, Saturday	17:10 - 18:30	Yuelong Lin	A Multi-Sectoral Co-Payment Model to Reduce Hepatitis C Treatment Costs and Advance Elimination Among Low-Income Populations: Experience from Yangjiang, China
1526	ORAL PRESENTATION 65	25 April 2026, Saturday	17:10 - 18:30	Yanfei Feng	Transcriptional Activity of cccDNA in HBsAg-Negative Individuals with a History of Hepatitis B Virus Infection
2649	ORAL PRESENTATION 65	25 April 2026, Saturday	17:10 - 18:30	Jie Bai	Microsomal Glutathione S-Transferase 2 Links Copper Toxicity to Hepatic Inflammation via Leukotriene C4 in Wilson's Disease
2871	ORAL PRESENTATION 65	25 April 2026, Saturday	17:10 - 18:30	KRISHNAKANTH SARDA	Genetic Variants in Bile Transporter Genes in Prolonged Cholestatic Jaundice Associated with HAV and Drug-Induced Liver Injury
1121	ORAL PRESIDENTIAL SESSION	24 April 2026, Friday	09:00 - 10:30	Xingru Wang	The first application and feasibility assessment of 5G-enabled remote robot-assisted hepatobiliary and pancreatic surgery in patients with malignant tumors
1380	ORAL PRESIDENTIAL SESSION	24 April 2026, Friday	09:00 - 10:30	Mengmeng Zhang	The SAFE-DILI Model for the Dynamic Prediction of Liver Transplantation or Death in Idiosyncratic Drug-Induced Liver Injury
1587	ORAL PRESIDENTIAL SESSION	24 April 2026, Friday	09:00 - 10:30	Qinshuo Wang	Remodeling of the bile acid connectome across the hepatitis-cirrhosis-hcc axis: network analysis reveals stage-specific hubs and potential therapeutic targets
2130	ORAL PRESIDENTIAL SESSION	24 April 2026, Friday	09:00 - 10:30	Ju Dong Yang	Predictors and impact of complete pathological response to pre-transplant immune checkpoint inhibitors in hepatocellular carcinoma: Findings from the Global LIFT-HCC consortium
2505	ORAL PRESIDENTIAL SESSION	24 April 2026, Friday	09:00 - 10:30	Cihan Yurdaydin	Lonafarnib as finite treatment for chronic hepatitis D: Long-term follow-up data